Interferon-alpha to augment merkel cell carcinoma immunotherapy response

Genetically modified cells expressing interferon-α, interferon-γ, and αβ TCRs, along with antigen-binding antibodies, are used to enhance anti-tumor immune responses and overcome ICB resistance in MCC patients, improving the efficacy of immunotherapy.

WO2024249828A1PCT designated stage expired Publication Date: 2024-12-05NORTHWESTERN UNIV +1

Patent Information

Application Number
PCT/US2024/031958
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Merkel cell carcinoma (MCC) patients often develop resistance to immune checkpoint blockade (ICB) therapy, limiting the efficacy of immunotherapy, and there is a need for mechanisms to overcome this resistance and enhance anti-tumor immune responses.

Method used

The use of genetically modified cells expressing interferon-α, interferon-γ, and αβ T cell receptors (TCR) to generate an anti-tumor immune response, combined with antibodies or antibody fragments that bind specific antigens, to enhance the immune system's ability to recognize and target tumor cells, thereby overcoming ICB therapy resistance.

Benefits of technology

This approach effectively generates a robust anti-tumor immune response, increasing the effectiveness of immunotherapy and overcoming resistance to ICB treatment in MCC patients by enhancing tumor-specific T cell responses and immune infiltration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024031958_05122024_PF_FP_ABST
    Figure US2024031958_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are novel compositions and methods using said compositions for treating Merkel cell carcinoma. More specifically, provided herein are compositions utilizing T cell receptors or combinations of cytokines, chemokines, and receptors that modulate the response of the immune system to detect and target cancer cells.
Need to check novelty before this filing date? Find Prior Art

Description

INTERFERON-ALPHA TO AUGMENT MERKEL CELL CARCINOMA IMMUNOTHERAPY RESPONCE CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No.63 / 505,642, filed June 1, 2023, the entire contents of which are incorporated herein by reference. STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under grant numbers P30AR075049, DP2 OD024475-01, and R35 GM144083 awarded by National Institutes of Health and T32 CA009560 and F30CA278298 awarded by the National Cancer Institute. The government has certain rights in the invention. TECHNICAL FIELD

[0003] This disclosure relates to a method of treating Merkel cell carcinoma (MCC). More specifically, this disclosure relates to a method of generating an anti-tumor response in a subject with Merkel cell carcinoma. BACKGROUND

[0004] The following description of the background of the present technology is provided simply as an aid in understanding the present technology and is not admitted to describe or constitute prior art to the present technology.

[0005] Merkel cell carcinoma (MCC) is a highly aggressive primary neuroendocrine skin cancer that has high rates of metastasis and recurrence. There are two subtypes of MCC, with different etiologies and phenotypes. In 60% to 80% of MCC cases, the Merkel cell polyomavirus (MCPyV) is mutated and clonally integrated into the genome of the tumor cells. The integrated MCPyV expresses obligate viral oncoproteins, including small and truncated large T antigens, which drive carcinogenesis in part by inactivating p53 and pRB. Whereas virus-positive (VP) MCCs inactivate pRB and p53 through the expression of the small and large T oncoproteins, virus-negative (VN) MCCs achieve the same molecular endpoint through near universal somatic mutation of both RB1 and TP53.1

[0006] VN MCCs are immunogenic because of the high number of tumor neoantigens that result from high mutation burdens. VP MCCs have a low mutation burden but are immunogenic because they constitutively express the viral oncoproteins. Shared antigens in VP MCCs facilitate the easy identification of tumor-specific T cells across patients.

[0007] For metastatic disease, immunotherapy is the only therapy approved by Food and Drug Administration (FDA) that significantly prolongs survival. Unfortunately, many patients have either primary (~50%) or acquired resistance (up to 25%) to immune checkpoint blockade (ICB) treatment. It is therefore important to identify potential mechanisms underlying this resistance to ICB treatment and develop methods to overcome the resistance to increase the efficacy of ICB immunotherapy. SUMMARY

[0008] The present disclosure provides novel compositions to treat MCC and methods of using the same for treatment. It is to be understood that the disclosed embodiments are merely exemplary, and accordingly, the invention may be embodied in various and alternative forms. The specific structural and functional details herein are not to be interpreted as limiting but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the embodiments described herein.

[0009] In a first aspect, provided herein are compositions for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), wherein the cellular composition comprises (i) one or more populations of cells genetically modified to express at least one of interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D,2 4882-8755-5522.2TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof; (ii) one or more populations of cells genetically modified to express one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to at least one of ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof; or (iii) a combination of (i) and (ii).

[0010] In a second aspect, provided herein are cellular compositions for generating an anti-tumor immune response in a subject with MCC, wherein the cellular composition comprises (i) one or more populations of cells genetically modified to express at least one of interferon-α, interferon- γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof; (ii) one or more populations of cells genetically modified to express one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to at least one of ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof; or (iii) a combination of (i) and (ii).3 4882-8755-5522.2

[0011] In a fourth aspect, provided herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating MCC in a subject comprising administering to the subject an effective amount of any of the compositions disclosed above.

[0012] In a fifth aspect, provided herein are methods of overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with MCC comprising administering to the subject an effective amount of any of the compositions disclosed above.

[0013] In a sixth aspect, provided herein are compositions for generating an anti-tumor immune response in a subject with MCC, the composition comprising one or more cells genetically modified to express an αβ T cell receptor (TCR).

[0014] In an seventh aspect, provided herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating MCC in a subject, the method comprising administering to the subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier.

[0015] In a eighth aspect, provided herein are methods of overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with ICB therapy resistant MCC, the method comprising administering to the subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIGS.1A, 1B, 1C, 1D, 1E, 1F, and 1G depict data showing differentially expressed genes identify key immune and tumor signatures distinguishing immunotherapy responders and non- responders. FIG.1A shows the patient sample heatmap of assays and clinical metadata for each sample in the dataset. Each column represents a single patient with the available assays and associated clinical characteristics. In total, 116 patients were included in the study.101 patients received immunotherapy.71 patients were assayed by bulk RNA-Seq, 64 by single cell (sc)RNA-Seq, 41 by multiplex immunofluorescence (mIF), and 20 by spatial transcriptomics (GeoMx and CosMx). Vp, Virus-positive; VN, Virus-negative. FIG.1B shows a schematic of the study overview. Patient characteristics, paraffin-embedded (FFPE) sample sequencing breakdown with sample counts, single-cell processing workflow with sample counts, and single-4 4882-8755-5522.2cell library breakdown with sample counts.54 tumor samples and 55 peripheral blood mononuclear cell (PBMC) samples were stained with 45 antibody-derived tags (ADT) and enriched for live, CD45+ cells (tissue), or CD3+ cells (PBMCs) via fluorescence-activated cell sorting (FACS). Cells were process using 10x Chromium, and four sequencing libraries were prepared for each sample: 5’ cDNA, ADT, αβ VDJ, and γδ VDJ. FIG.1C shows the volcano plot of differentially expressed (DE) genes between immunotherapy (IO) responders (R) and non- responders (NR). Bulk RNA-Seq was conducted on 63 FFPE tumor samples from 62 immunotherapy naïve, systemic therapy naïve patients, all samples prior to evaluable responses to immune checkpoint blockade (ICB). Differentially expressed genes were identified using the DESeq2 package with the following covariates: sex, viral status, and tissue. Selected protein- coding genes with a false discovery rate (FDR) less than 0.1 were labeled. A total of 800 genes were upregulated in responders, and 436 genes were upregulated in non-responders. FIG.1D shows the pathway analysis of differentially expressed (DE) genes in responders. Only protein- coding genes with FDR less than 0.1 were included in the analysis. The top five enriched gene sets from the selected gene set libraries are shown for the responder DE genes. Gene sets were ranked based on the Enrichr combined score, which is a measure of both Fisher’s exact test p- value and the z-score of the derivation from the expected rank of the gene set. FIG.1E shows the three gene sets enriched in responders with associated genes represented on the volcano plot of DE genes from responders and non-responders. Genes with FDR less than 0.1 are labeled. FIG. 1F shows the enrichment gene list analysis of DE genes found in non-responders. Only protein- coding genes with FDR less than 0.1 were included in the analysis. The top five enriched gene sets from the selected gene set libraries are shown for non-responder DE genes. Gene sets were ranked based on the Enrichr combined score. FIG.1G shows the two gene sets enriched in non- responders with associated genes represented on the volcano plot of DE gene from responders and non-responders. Only genes with FDR less than 0.1 are labeled.

[0017] FIGS.2A, 2B, and 2C depict the patient level heatmaps by assay. FIG.2A shows the patient sample heatmap of assays and clinical metadata for each bulk RNA-Seq sample in the dataset. Each column represents a single patient with the available assays and associated clinical characteristics.71 patients were assayed by bulk RNA-Seq. VP, Virus-positive; VN, Virus- negative. FIG.2B shows the patient sample heatmap of assays and clinical metadata for each scRNA-Seq sample in the dataset. Each column represents a single patient with the available5 4882-8755-5522.2assays and associated clinical characteristics.64 patients were assayed by scRNA-seq. FIG.2C shows the patient sample heatmap of assays and clinical metadata for each mIF, GeoMx, or CosMx sample in the dataset. Each column represents a single patient with the available assays and associated clinical characteristics.41 patients were assayed by mIF, 12 patients by GeoMx, and 12 patients by CosMx.

[0018] FIG.3 depicts the overview of modalities in the database. The figure shows the upset plot of each intersection of assay modalities by sample. Numbers represent the number of assays. mIF, multiplex immunofluorescence; sc, single cell.

[0019] FIG.4 depicts the flow chart illustrating the computation pipeline for single cell RNA- Seq data processing.

[0020] FIGS.5A, 5B, 5C, 5D, and 5E depict the quality control metrics of the tissue single cell dataset. FIG.5A shows the Uniform Manifold Approximation and Projection (UMAP) projection of all tissue scRNA-Seq cells without batch correction labeled by the major cell type. FIG.5B shows the UMAP projection of the same dataset before batch correction and after batch correction with Harmony, labeled by patient sample. FIG.5C show a bar chart showing the number of filtered cells per sample (top panel) and a stacked bar chart showing the uncorrected proportion of each cell type in each sample (bottom panel). FIG.5D shows violin plots of quality control metrics, including the number of RNA unique molecular identifiers (UMIs), number of detected genes, number of antibody-derived tags (ADTs), and mitochondrial (MT) gene percentage per sample. The bottom panel is a bar chart showing the number of αβ and γδ TCRs detected for each sample. FIG.5E shows the same plots as D but split by cell type.

[0021] FIG.6 depicts the cell type clusters in the single-cell PBMC dataset. Cells from the blood single-cell dataset were clustered with both antibody-derived tag (protein) and RNA data using weighted nearest neighbor (WNN) clustering. Marker gene expression was determined using a Wilcoxon test.

[0022] FIGS.7A, 7B, 7C, 7D, 7E, 7F, 7G, 7H, and 7I depicts data showing the response to ICB is associated with tumor cell upregulation of an interferon-γ signature and negatively correlated with a tumor cycling signature. FIG.7A show the UMAP projection of 139,845 cells among all6 4882-8755-5522.249 tissue samples in single-cell (sc) transcriptome datasets with major cell-type annotation. PCA inputs were batch-corrected using the Harmony package, and cells were clustered using the standard Seurat pipeline. FIG.7B shows a dot plot showing the scaled expression of the top five marker gene for each cell type annotated in the tissue scRNA-Seq dataset. FIG.7C shows the differential gene expression analysis of 60,902 tumor cells pseudobulked by tissue sample between ICB responder and non-responders, which was performed using the edgeR LRT test with sex and virus status as covariates.34 gene were upregulated in responders, and 25 genes were upregulated in non-responders. Protein-coding genes with FDR less than 0.25 are labeled. FIG.7D shows the gene set enrichment analysis (GSEA) of DE genes found in immunotherapy responders (R) and non-responders (NR). Hallmark gene sets were ranked by normalized enrichment score (NES), with the top 5 gene sets from responders and non-responders listed. *** p adjust < 0.001, ** p adjust < 0.01, * p adjust < 0.05. FIG.7E shows the results of the SCENIC regulon analysis run on 60,902 tumor cells. The top 5 regulons differentially expressed in responders (R) and non-responders (NR) are shown, ranked by false discovery rate (FDT), Wilcoxon test. FIG.7F shows a scatter plot of CD45+ infiltration (% CD45+ cells from FACS) with logit transformation versus Hallmark Interferon-γ signature model score in tumor cells from scRNA-Seq, which depicts a positive Pearson correlation between interferon-γ response in the tumor and overall immune infiltration. Samples are colored according to ICB response. IFNG score was calculated on tumor cells by the ModuleScore function in Seurat using the MSIGDB “Hallmark Interferon Gamma Response” genes as input. FIG.7G shows a volcano plot of IFNG expression of each cell type split by samples and ranked by mean expression. FIG.7H shows scatter plots of immune proportion (% CD45+ cells from FACS) with logit transformation or tumor cell IFNG score compared to the proportion of proliferating tumor cells among the total cells with log transformation in each scRNA-Seq tissue sample. Samples are colored by ICB response, which shows a negative Pearson correlation between the proportion of proliferating tumor cells and either the immune infiltration or IFNG response in the tumor cells, with non- responders clustered in the high proliferation, low IFNG or low CD45+ % quartile. FIG.7I shows a Kaplan-Meier curve of post-immune checkpoint blockade survival, showing that samples with higher levels of the tumor cycling cell signature (derived from scRNA-Seq) had lower survival. Samples from the bulk RNA-Seq dataset were scored based on “tumor cycling”7 4882-8755-5522.2cell type signature derived from the single cell data with gene set variance analysis (GSVA) and split into the top or bottom quartile. The statistical test used is the Cox proportional hazards test.

[0023] FIGS.8A and 8B depict myeloid cells in Merkel cell carcinoma. FIG.8A shows the UMAP projection of the myeloid cell subset from the tissue single-cell RNA-Seq dataset colored by major myeloid cell types. Mac, macrophage; mono, monocytes; cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells. FIG.8B shows the Pearson correlation of interferon-α signature model score in tumor cells, T / NK cells, and stromal cells versus the proportion (log transformed) of plasmacytoid dendritic cells (pDC) in tumor samples. These plots show a significant correlation between pDC and IFN-α responses in multiple cell types.

[0024] FIGS.9A and 9B depict the data showing response to ICB is associated with tumor cell upregulation of an interferon-γ signature. FIG.9A shows the UMAP projection with the density of IFNG expression for all cells in the MCC TME, showing that the expression of IFNG was highest in the CD8 T cell cluster. This is the same UMAP projection as in FIG.7A. FIG.9B shows the bulk RNA-Seq dataset, consisting of 63 total sample, of which 43 samples were from the skin, 17 were from the lymph node (LN), and the remaining three from visceral organs.42 of the samples were primary tumors, and 21 of the samples were metastases. Differential expression analysis was run comparing responders to non-responders in each subgroup (skin only, LN only, primary only, and metastatic only). Next, GSEA pathway analysis was used to look at upregulated pathways in responders from the MSigDB Hallmark gene dataset.

[0025] FIGS.10A and 10B depict the GSEA on tumor cells controlling for proliferation. FIG. 10A shows tumor cells subsetted from the single cell dataset with proliferating tumor cells removed. Pseudobulk differentially expression analysis was run on these samples and then processed with Gene set enrichment analysis. Hallmark pathways are shown, ranked by normalized expression score (NES) and colored if significant (p adjust <0.1). FIG.10B shows tumor cells subsetted from the single cell dataset and scored using the CellCycleScoring function in Seurat. Pseudobulk differentially expression analysis was run with average cell cycle score as a covariate on these samples and then processed with Gene set enrichment analysis. Hallmark pathways are shown, ranked by normalized expression score (NES) and colored if significant (p adjust <0.1).8 4882-8755-5522.2

[0026] FIGS.11A, 11B, 11C, 11D, 11E, 11F, 11G, 11H, 11I, and 11J depict data showing CD8 TILs form two distinct developmental trajectories composed of circulatory T cells and tissue resident memory subsets. FIG.11A shows the UMAP projection of 24,448 CD8 T cells in 15 cell clusters. Outlines of the clusters show the formation of two meta-clusters: circulating T cells (Tcirc) and tissue-resident memory T cells (Trm). Cells were subset from all tissue scRNA-Seq samples and clustered using the standard Seurat pipeline. FIG.11B shows the heatmap of the antibody-derived tag (ADT) protein average scaled expression of each CD8 cluster with hierarchal clustering into two major meta-clusters distinguishing Tcirc and Trm cells. FIG.11C show a bar chart of the proportion of co-expressing, co-inhibitory markers statistically enriched on T resident memory (Trm) compared to T circulatory (Tcirc) cells (χ2, p <2.2e-16). FIG.11D shows a dot plot of selected average marker gene expression for each CD8 lineage with functionally grouped genes. logFC, log2 fold change. FIG.11E shows a diffusion mapping projection of CD8 T cells with cell cycle genes regressed out using the Destiny package. The diffusion map shows two separate lineages, which are colored by Trm and Tcirc. Cells in the CD8 cluster C04 are depicted in grey. C04 shows characteristics of both Trm and Tcirc cells. DC, diffusion component. FIG.11F shows a heatmap of the log-likelihood ratio (LLR) of shared TCR clones between CD8 clusters with the heatmap clustered by LLR demonstrates the formation of two meta-clusters that match the Trm and Tcirc lineages. *, p < 0.05, Fisher’s test. FIG.11G shows a bar chart of all expanded CD8 clonotypes in the tissue dataset. Each line represents the proportion of cells in each lineage of the single clonotype. The clonotypes were ranked from the highest proportion of cells in the Trm lineage to the lowest proportion (highest in the Tcirc lineage). For 88% of the clonotypes, 100% of the cells were restricted to either the Trm or Tcirc lineage. FIG.11H shows a bar chart of the proportion of clones that were also found in the PBMC single-cell dataset split by developmental lineage. Only matched blood samples were including in this analysis. Chi-squared test for significant differences between proportions were used. FIG.11I shows the UMAP projection (same as in FIG.11A) colored by TCR clone size. FIG.11J shows the violin plots of clonal size of all clonotypes found in the Trm or Tcirc lineage.

[0027] FIG.12 depicts the dot plot of the average expression of RNA markers in each CD8 cluster in the tissue samples. Clusters are divided by developmental lineage: tissue-resident memory (Trm) or circulatory T cell (Tcirc).9 4882-8755-5522.2

[0028] FIGS.13A and 13B depict the clonotype distribution between CD8 T cell lineages. FIG. 13A shows the cell density plots of the top 20 expanded CD8 clones (ranked by number of cells per clone) in the tissue scRNA-Seq dataset. The cells were projected onto the same UMAP as in FIG.11A. The top red dotted line represents the boundary of Tcirc cells. The bottom blue dotted line represents the boundary of the Trm cells. FIG.13B shows the histograms of 100% restricted clonotypes from a Monte Carlo simulation, where T cells in the clonotypes of the CD8 TCR tissue dataset were randomly assigned to Trm or Tcirc. The simulation was repeated 1e6 times. The dashed red line represents the actual restriction observed in the dataset.

[0029] FIGS.14A, 14B, 14C, and 14D depict CD8 lineage characterization. FIG.14A shows the UMAP projection of Tcirc cells colored by Monocle 3 pseudotime differentiation. FIG.14B shows the expression of selected genes across Tcirc pseudotime with cells colored by cluster. FIG.14C shows the UMAP projection of Trm cells colored by Monocle 3 pseudotime differentiation. FIG.14D shows the expression of selected genes across Trm pseudotime with cells colored by cluster.

[0030] FIGS.15A, 15B, 15C, and 15D depict the clonality and neoantigen metrics of CD8 T cells. FIG.15A shows a box plot of the Gini index of each CD8 cluster separated by sample and ordered by Gini index. Clusters associated with Trm have higher overall Gini indices. FIG.15B shows a bar chart of clonal distribution of each CD8 cluster. Each horizontal line represents a cell in a cluster, colored according to the clonal size of the cell. The largest clone sizes are associated with Trm clusters. FIG.15C shows a box plot of the Neo TCR8 score of each CD8 sample separated by MCC viral status. VP, Virus-positive; VN, Virus-negative. FIG.15D shows a violin plot of the Gini index of CD8 T cell receptor clonotypes for each sample, split by viral status.

[0031] FIGS.16A, 16B, 16C, 16D, 16E, 16F, 16G, 16H, and 16I depict data showing that CD8 Trm cells are tumor specific and prognostic of ICB response. FIG.16A shows a violin plot of cellular expression of the NeoTCR8(23) module score split by CD8 cluster. Clusters are colored by developmental lineage: T circulatory cells (Tcirc) and T resident memory cells (Trm). FIG. 16B shows a cell density plot showing the distribution of cells with the MO_MCC_095c1 TCR clonotype, a highly expanded Trm TCR clone found in virus-positive MCC samples. The outline10 4882-8755-5522.2shows the distribution of Tcirc and Trm cells. FIG.16C shows the results of the NFAT-GFP reporter experiment. Jurkat-76 cells modified with an NFAT-GFP reporter and CD8α / CD8β were transduced and selected to express the MO_MCC_095c1 TCR. These cells were co- cultured with an autologous lymphoblastoid cell line loaded with pooled peptides from the small and large T antigens of Merkel cell polyoma virus. After co-culture, GFP expression on the reporter cells was measured as a measure of antigen recognition, leading to T cell activation. CEF (CMV, EBV, influenza) peptide pool, pool 1, pool 2, and pool 3 are representative examples of negative hits, whereas pool 8 and pool 12 are positive hits. The complete results for all pools can be found in FIG.18. *, p < 0.05, One-way ANOVA. FIG.16D shows a structural model of the MO_MCC_065c1 TCR in complex with its target peptide, small T (sT) antigen residues 31-39, bound to its putative MHC allele, HLA B*07:02. This model reveals a canonical TCR-pMHC binding mode and multiple polar contacts that stabilize the interaction (dashed lines). TCRα is shown in magenta, TCRβ in cyan, and the peptide in slate (stick representation), and MHC in green. The high confidence of the model by AlphaFold score, 0.82 out of 1, indicates a high likelihood of structural accuracy. FIG.16E shows a scatter plot of all significant GLIPH2 complementary- determining region 3 (CDR3) motifs found in the CD8 tissue TCR dataset. The axis has been adjusted to show motifs that are more than 80% found in virus- positive samples and more than 80% found in Trm cells. These virus-positive (VP) Trm motifs are shared between multiple patients and are highly expanded and represent likely shared anti- MCC TCR motifs. “%” indicates a variable amino acid found in the GLIPH motif. FIG.16G shows representative multiplex immunofluorescence (mIF) images showing skin resident CD8 T cells (CD3+ CD8+ CD103+) infiltrating the tumor parenchyma, marked by pan-cytokeratin (PanCK), and are cytotoxic, marked by granzyme B (GZMB). Scale bar represents 100 μm. FIG. 16G shows a scatter plot of tissue-resident CD8 T cell densities (percentage of CD3+ CD8+ expressing CD103 per mm2) from 29 mIF samples from 26 patients (17 responders and 9 non- responders). The statistical test used is a Wilcoxon test. FIG.16H shows a violin plot of the ratio of Trm to Tcirc cells split by response to immunotherapy (IO). The statistical test used is a Wilcoxon test. FIG.16I shows a Kaplan-Meier curve of survival from the start of ICB from the bulk RNA-Seq dataset. Samples ere split based on the top and bottom quartiles of the Trm gene set variation analysis score from the single-cell dataset. The statistical test used is a Cox proportional hazards test.11 4882-8755-5522.2

[0032] FIGS.17A, 17B, and 17C depict comparisons of cell type signature and cell proportions separated by sample of origin. The bulk RNA-seq dataset consisted of 63 total samples, of which 43 samples were from the skin, 17 were from the lymph node (LN) and the rest being from visceral organs.18 samples were stage I / II, 37 samples were stage III, 8 samples were stage IV. The single cell dataset consisted of 40 skin samples, 8 LN samples and 1 adrenal sample.28 of the samples came from primary tumors and 21 samples came from metastatic tumors. FIG.17A shows the. Violin plots of signature GVSA scores for bulk RNA seq samples of cell type signatures and IFNG signature. FIG.17 B shows violin plots of signature GSVA scores for bulk RNA-Seq samples. The statistical test used is a Wilcoxon test. FIG.17C shows the violin plots of the relative cell percentages for CD8 Trm, CD8 Tcirc, Vδ1 / Vδ3, and Vδ2 cell types in the tissue single cell RNA-seq dataset separated by tissue type or metastatic status. Wilcoxon test.

[0033] FIGS.18A, 18B, 18C, 18D, 18E, and 18F depict epitope screening results. FIG.18A shows the flow cytometry gating strategy of the TCR epitope screen to identify CD69+ GFP+ Jurkat-76 cells. FIG.18B shows a table depicting the two-dimensional matrix of peptide pools showing the two pools that caused upregulation of CD69 and an NFAT-GFP reporter in transduced CD8 Jurkat-76 cells, thus identifying common T (CT) amino acids 29-41 as the targeted antigen of MO_MCC_095c1 TCR. The table on the left shows the peptides in each pool, colored by the normalized (to DMSO) CD69+ GFP+ percentage. The first two letters identify the protein, and the numbers identify the amino acids. The table on the right shows the normalized values of CD69 and GFP expression. ST, small T antigen; LT, large T antigen. FIG.18C shows a table of the two-dimensional matrix of peptide pools, showing the two pools that caused upregulation of CD69 and an NFAT-GFP reporter in transduced CD8 Jurkat-76 cells, thus identifying large T (LT) amino acids 189-201 as the targeted antigen of NU_MCC_005c131 TCR. FIG.18D shows a table of the two-dimensional matrix of peptide pools, showing the two pools that caused upregulation of CD69 and an NFAT-GFP reporter in transduced CD8 Jurkat- 76 cells, thus identifying large (LT) amino acids 97-109 as the targeted antigen of MO_MCC_071c1 TCR. FIG.18E shows a table of the two-dimensional matrix of peptide pools, showing that none of the pools caused upregulation of CD69 and an NFAT-GFP reporter in transduced CD8 Jurkat-76, in a Tcirc expanded TCR, MO_MCC_092c1 TCR. FIG.18F shows a total of 4 highly expanded TCRs that were screened for MCPyV epitopes. The putative peptide- MHC complex was determined by NetMHCPan. The TCR was then modeled with the peptide-12 4882-8755-5522.2MHC complex using TCRmodel2, which gives a score out of 1 to indicate the confidence of the model.

[0034] FIGS.19A and 19B depict public epitopes. FIG.19A shows the UMAP projection (same as FIG.11A) with CD8 T cells colored according to the database clonotype. TCR sequences were compared to three publicly available databases, and T cells with clonotypes that matched the databases were identified. The public often anti-viral (not MCPyV) TCRs were enriched in the Tcirc lineage (top half of UMAP), p = 0.00001, Chi-squared test. FIG.19B shows a violin plot of the absolute percentage of Tcirc and Trm cells in the sample, showing that only Trm cells showed a significant increase in responders.

[0035] FIGS.20A and 20B depict the GeoMx quality control for regions of interest. FIG.20A shows the region of interest (ROI) classification. The ROI classification was separated by response to immunotherapy after the tissue was collected and grouped by patient samples. PD, progressive disease; CR, complete response. FIG.20B shows the box plots of the raw transcript reads and sequencing saturation for each ROI, split by panel. The points are colored in the patient sample. CTA, cancer transcriptome analysis; WTA, whole transcriptome analysis.

[0036] FIGS.21A and 21B depict the GeoMx image and differential expression analysis. FIG. 21A shows a representative section from a tumor sample that responded to immunotherapy and was used for GeoMx. Regions of interest (ROIs) that were assayed by GeoMx are highlighted, showing the diversity of tumor and stroma regions that were sequenced for each sample. PanCK, pan-cytokeratin (a tumor marker). The scale bar is equal to 2 mm. FIG.21B shows differentially expressed genes by scran package (multiple T tests) in 74 stroma ROIs or 106 tumor ROIs, comparing samples from complete responders (CR) to samples from progressive disease (PD). Complete responders in the stroma showed an interferon-gamma (IFN-^) response (GBP4, HLA-I, TAP, and proteasome genes), T cell markers (CD27 and CD7), B cell markers (CD79A, POU2AF1), and macrophage markers (C1QB, CD68, CD163). Non-responders had tumor markers (keratins, PRAME) and proliferation markers (TYMS, MCM, E2F1). Within the tumor region of responders (CR), we observed both T cell genes (LAG3, GZMB, TRDC) and interferon response genes (GBP4), whereas in non-responders (PD), there was prominent13 4882-8755-5522.2expression of tumor markers (keratins, CD44, and HOX genes) and proliferation markers (TYMS and MKI67). The selected labeled genes had Padj. < 0.05.

[0037] FIGS.22A, 22B, 22C, 22D, 22E, 22F, 22G, 22H, 22I and 22J depict the spatial and temporal analysis of tumor infiltrating lymphocytes. FIG.22A shows the violin plots of the relative expression of GeoMC regions of interest (ROI) of tissue resident memory (Trm) / circulatory T (Tcirc) signature genes, derived from the scRNA-Seq dataset, by module score in the stroma or tumor parenchyma. FIG.22B shows the UMAP projection of 614,209 cells segmented using the CosMx assay. The cells are colored according to the inferred cell type. Cells were clustered in Seurat and batch-corrected using SCTransform. FIG.22C shows an unsupervised hierarchical clustering heatmap of cell type co-localization as measured by the degree of co-localization (DoC) within CosMx fields of view (FOV). Neighboring cells were identified within a 54 micron radius of each cell, and then the DoC was determined using the SpatialTIME(34) method. A high degree of co-localization was observed among T cells, B cells, DCs, and pDCs is outlined in the upper left. Ave, average; Mac, macrophages; Endo, endothelial cells; Fibro, fibroblasts; Tumor cyc, tumor cycling cells; pDC, plasmacytoid dendritic cells; DC, dendritic cells; Epi, epithelial cells; Mono, monocytes. FIG.22D shows a sample FOV showing co-localization of T cells, B cells, and pDC at the tumor-stroma interface using CosMx cell segmentation representation (left) and morphological markers, showing para-nuclear dot-like expression of Pan cytokeratins (CK), with high CD298 expression across immune cells. The scale bar is 50 μm. FIG.22E shows bar charts of the cell types found in T cell neighborhoods (54 μm radius), showing prevalence of pDC, DC, and B cells in T cell neighborhoods of responders (R) versus T cell neighborhoods of non-responders (NR). Comparisons were made using the Chi- squared test. ****, p value < 2.2e-16. FIG.22F shows a dot plot of receptor-ligand interactions from CellChat on the scRNA-Seq dataset, identifying multiple activating chemokines, cytokines, and surface receptor interactions between B cells, DCs, and pDCs to exhaustion, CD8 Trm cells (CD8 Tex.). FIG.22G shows the differential gene expression analysis (DE-Seq2) comparing matched pre- versus post-ICB sample pairs across 7 non-responders and 7 responders, showing upregulation of inflammatory genes after ICB treatment. Among responders, 1560 genes were unregulated and 995 genes were downregulated after therapy. (DE-Seq2, Padj< 0.1). Only two differentially expressed genes were identified among the non-responders. FIG.22H shows Enrichr gene list analysis of DE genes in pre- versus post-ICB matched pairs from responders,14 4882-8755-5522.2showing inflammatory pathways upregulated and cell cycle pathways downregulated after treatment. Only protein-coding genes with FDR less than 0.1 were included in the analysis. The top five enriched gene sets from the Hallmark gene set libraries are shown for the DE genes. Gene sets were ranked based on the Enrichr combined score, which is a measure of both Fisher’s exact test p-value and the z-sore of the derivation from the expected rank of the gene set. FIG. 22I sows the corrected cellular proportions of Trm cells in 15 post-ICB treated samples, showing CD8 Trm infiltration is higher (3.01-fold) in partial responders (PR) versus progressive disease (PD) after treatment. Samples are split by response prior to biopsy. Five of the samples represent a new cohort of post-ICB samples used to verify results from the original scRNA-Seq data. The statistical test used is a Wilcoxon test. FIG.22J shows the violin plots of CD8 cells in MO_MCC_079 and MO_MCC_085, two scRNA-Seq pre / post sample pairs. Exhaustion score expression was split by treatment timeline and grouped by clonotype expansion, showing that expanded cells were more likely to be exhausted pre-treatment, with exhaustion levels significantly decreased after treatment. The exhaustion score was derived from Seurat AddModuleScore.

[0038] FIGS.23A, 23B, 23C, and 23D depicts the CosMx quality control for fields of view. FIG.23A shows the field of view (FOV) classification separated by response to immunotherapy after the tissue was collected and grouped by patient sample. PD, progressive disease; CR, complete response; PR, partial response; IO, immunotherapy. FIG.23B shows the box plots of the raw transcript reads for each FOV, split by slide. FIG.23C shows the box plots of the targets detected per cell for each FOC, split by slide. FIG.23D shows the Euler plots of the differentially expressed (DE) gene overlap from the CITE-Seq dataset (49 tissue samples) versus the CosMx dataset (13 samples) for tumor cell and T cells. DE genes from the CITE-Seq dataset are depicted in red. DE genes from the CosMx data are depicted in green for each cell type.

[0039] FIGS.24A, 24B, 24C, 24D, and 24E depict the CosMx degree of co-localization sensitivity test, showing B cell, T cell, pDC, and DC interactions. FIG.24A shows a heatmap of the degree of co-localization (DoC) calculated using the spatialTIME package between cell types from the CosMx dataset. The radius of 250 μm is approximately 45 μm for each cellular neighborhood. Hierarchical clustering showed a high degree of pairwise co-localization between pDC (plasmacytoid dendritic cells), DC (dendritic cells), T cells, and B cells, and supports the15 4882-8755-5522.2co-localization of these cells across a range of radii. Mono, monocytes; Endo, endothelial cells; Fibro, fibroblasts; Mac, macrophages; Epi, epithelial cells; Tumor c, tumor cycling cells. FIG. 24B shows a heatmap similar to FIG.24A but with a radius of 300, approximately 54 μm. FIG. 24C shows a heatmap similar to FIG.24A but with a radius of 400, approximately 72 μm. FIG. 24D shows a heatmap similar to FIG.24A but with a radius of 500, approximately 90 μm. FIG. 24E shows pie charts and bar charts, showing the relative proportion of each cell type within T cell neighborhoods split between responders and non-responders.

[0040] FIGS.25A, 25B, and 25C depict pre / post genes. FIG.25A shows a Euler diagram of gene overlap of two gene sets in the study. The first gene set represents the genes upregulated in 31 responders from the original 63 bulk RNA-Seq dataset, pre-ICB (723 protein-coding genes in blue / purple). The second gene set represents the new genes identified of responders after ICB treatment (949 protein-coding genes in red / purple). The 206 gene overlap is highly significant, p = 1.9e-179, hypergeometric test. FIG.25B shows box plots of GSVA scores on 14 sets of matched pre / post ICB treatment bulk RNA-Seq samples. GSVA scores are derived from cell type signatures. The Trm, Vδ1, and IFNG signature is only increased in responders, whereas the Tcirc signature is not significantly upregulated. FIG.25C shows the box plot of 15 post- treatment ICB samples, including 5 additional samples, analyzed for relative cell type proportions. Cell types were defined by clusters shown in FIGS.7A and 11A. Box plots of corrected, absolute proportion of tumor cycling cells in post-treatment single cell RNA-Seq samples. Plots are grouped by ICB response prior to sample collection. Partial responders (PR) show decreased cycling tumor cells (11.1-fold) after ICB treatment compared to progressive disease (PD).

[0041] FIGS.26A, 26B, 26C, and 26D depict the MIXCR analysis of pre / post ICB clonal dynamics. FIG.26A show alluvial plots of TCR beta chain (TRB) clonotype size pre- and post- treatment in ICB responders and non-responders. Clonotypes were called on bulk RNA-Seq samples using MIXCR. Responders showed a mixture of clonal replacement and clonal expansion post-treatment. Non-responders showed few, if any, clones defined by clonal replacement. FIG.26B show alluvial plots of immunoglobulin heavy chain (IGH) clonotype size pre- and post-treatment in ICB responders and non-responders. Responders showed a mixture of clonal replacement and clonal expansion post-treatment. Non-responders showed few, if any,16 4882-8755-5522.2clones defined by clonal replacement. FIG.26C show bar plots showing the percentage of TRB. Reads that are un-expanded and found in only one sample are shown in grey. Clones in pre samples shared with post samples and expanded are in blue. Expanded clones unique to pre samples are in green. Expanded clones only found in post samples that are expanded are in orange. FIG.26D show a summary of all the reads normalized to counts per 1e6 reads of TRB clones for non-responders and responders after ICB. The size of the pie chart is proportional to the number of reads in each group. The colors match the groups in FIG.26C.

[0042] FIGS.27A, 27B, and 27C depict the single cell analysis of pre / post ICB clone dynamics. FIG.27A shows alluvial plots of TCR clonotype size pre- and post-treatment from the single-cell TCR dataset in two pre / post matched tissue samples. FIG.27B shows alluvial plots of TCR clonotype size pre- and post-treatment from the single-cell TCR dataset in two pre / post matched tissue samples with additional matched blood, showing that the top expanded clones in the tumor were not found in the blood. FIG.27C shows violin plots of CD8 cells in MO_MCC_079 and MO_MCC_085 split by treatment timeline and grouped by clonotype expansion, showing that expanded cells were more likely to be CD103+ and exhausted pre-treatment, with exhaustion levels significantly decreased after treatment. The exhaustion score was derived from Seurat AddModuleScore. Panels with ADT were derived from the protein markers.

[0043] FIGS.28A and 28B shows that CD8 T cell resident memory (Trm) cells begin in the inactivated, naïve-like state with polyclonal, unexpanded T cell receptors (TCR). They are marked by CD103 and CXCR6 in both the inactivated and activated states. Activation leads to oligoclonal expansion of tumor-specific TCRs, which are found to have shared motifs between patients. CD8 Trm cells were found to infiltrate MHC-high and IFNG-high tumors. Upon activation, they both express activation (CD38 and 41BB) and exhaustion markers (PD-1, LAG3, TIM-3, TIGIT, CTLA-4, and CD39). Finally, they express the same transcription factors (BATF, RUNX3, EOMES, STAT3) and effector molecules (GZMB, PRF1, IFNG, CXCL13). FIG.28B shows a table showing the phenotypic characteristics of CD8 T circulatory cells (Tcirc) versus CD8 T resident memory cells (Trm) cells. ICB, immune checkpoint blockade; TCR, T cell receptor; CDR3, complementary-determining region 3.17 4882-8755-5522.2

[0044] FIG.29 depicts a graphical model of immune checkpoint response in MCC. Tissue- resident CD8 T cells are the primary effectors of the anti-Merkel cell carcinoma (MCC) response to treatment with immune checkpoint blockade (ICB). They can be activated by B cell or plasmacytoid dendritic cell (pDC) co-stimulation and by interferon-γ or interferon-α secreted by CD8 T cells and pDCs, respectively. Factors that correlate with ICB resistance include interleukin-1 expression in myeloid cells, increased tumor proliferation and mTORC1 signaling. Neural stem cell transcription factor expression (i.e. OTX2) and an initial immune desert phenotype also favor resistance to ICB. DETAILED DESCRIPTION

[0045] Provided herein are compositions and methods for treating Merkel cell carcinoma. More specifically, the compositions include TCR receptors that recognize MCC antigens and cells comprising the TCR receptors. The compositions also include chemokines, cytokines, and receptors that may affect the dynamics of the immune response in order to modulate the ability of the immune system to recognize and target tumor cells.

[0046] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology. It is to be understood that the present disclosure is not limited to particular uses, methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein for the purpose of describing particular embodiments only and is not intended to be limiting. I. Definitions

[0047] Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. For example, reference to a “a cell” includes a combination of two or more cells, and the like. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular18 4882-8755-5522.2genetics, organic chemistry, analytical chemistry and nucleic acid chemistry and hybridization described below are those well-known and commonly employed in the art.

[0048] As used herein, the term “about” in reference to a number is generally taken to include numbers that fall within a range of 1%, 5%, or 10% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).

[0049] As used herein, the term “antigenic specificity” means that the T cell receptor (TCR) can specifically bind to and immunologically recognize a specific antigen with high avidity. Specifically, a TCR can be considered to have antigen specificity for a particular antigen if the T cells expressing the TCRs secrete more interferon-γ when co-cultured with the antigen than when cultured without the antigen. Further, a TCR can be considered to have antigen specificity for a particular antigen if the T cells expressing the TCRs upregulate expression of one or more T-cell activation markers as measured by, for instance, flow cytometry after stimulation with target cells expressing the antigen. Examples of T-cell activation markers include, but are limited to, 4-1BB, OX40, CD107a, CD69, and cytokines that are upregulated upon antigen stimulation (e.g., tumor necrosis factor (TNF), interleukin-2 (IL-2), etc.).

[0050] The term “polypeptide,” as used herein, refers to a single chain of amino acids connected by one or more peptide bonds. Polypeptide includes oligopeptides. The term “protein,” as used herein, means a molecule comprising one or more polypeptide chains.

[0051] As used herein, the term “nucleic acid” includes “polynucleotide,” “oligonucleotide,” and “nucleic acid molecule” and generally means a polymer of DNA or RNA, which can be single- stranded or double-stranded. The nucleic acid may contain natural, nonnatural, or altered nucleotides. The nucleic acid can contain natural, non-natural, or altered internucleotide linkages, such as a phosphoroamidate linkage or a phosphorothioate linkage instead of the phosphodiester found between nucleotides of an unmodified oligonucleotide.

[0052] As used herein, the term “expression vector” means a genetically-modified oligonucleotide or polynucleotide construct that permits the expression of an mRNA, protein, polypeptide, or peptide by a host cell, when the construct comprises a nucleotide sequence19 4882-8755-5522.2encoding the mRNA, protein, polypeptide, or peptide, and the vector is contacted with the host cell under conditions sufficient to have the mRNA, protein, polypeptide, or peptide expressed within the cell. The vectors are not naturally occurring but can comprise parts that are naturally occurring. The expression vectors can comprise any type of nucleotide, including, but not limited to, DNA or RNA, which can be single-stranded or double-stranded, synthesized or obtained in part from natural sources, and which can contain natural, nonnatural, or altered nucleotides.

[0053] As sued herein, the term “therapeutically effective amount” with reference to a composition disclosed means a dose regimen of the composition that provides the specific pharmacological effect for which the composition is administered to a subject in need of such treatment. For treatment, a therapeutically effective amount may be effective to reduce, ameliorate, or eliminate one or more signs or symptoms associated with a disease, delay disease progression, prolong survival, decrease the dose of other medication(s) required to treat the disease, or a combination thereof. A therapeutically effective amount may vary based on, for example, one or more of the following: the age and weight of the subject, the subject’s overall health, the stage of the subject’s disease, the route of administration, and prior or concomitant treatments.

[0054] “Administration” of a disclosed composition encompasses the delivery to a subject of a composition as described herein using any suitable formulation or route of administration, as discussed herein. Administration may comprise one or more (e.g., one, two, three, or more) dosing cycles. Administration may comprise oral administration, parenteral administration, intratumoral administration, or any administration method suitable for treatment with the compositions. The term “co-administration,” “administered in combination with,” and their grammatical equivalents, as used herein, encompasses administration of two or more agents to the subject so that both agents and / or their metabolites are present in the subject at the same time. Co-administration includes simultaneous administration in separate compositions, administration at separate times in separate compositions, or administration in a composition in which both agents are present.

[0055] As used herein, the terms “"treatment", "treating", "palliating" “managing” and "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining20 4882-8755-5522.2beneficial or desired results including, but not limited to, therapeutic benefit and / or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disorder. For prophylactic benefit, the pharmaceutical compounds and / or compositions can be administered to a patient at risk of developing a disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

[0056] The terms “patient,” “subject,” and “individual” may be used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).

[0057] "Pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The pharmaceutically acceptable carrier or excipient does not destroy the pharmacological activity of the disclosed compound and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions as disclosed herein is contemplated. Non-limiting examples of pharmaceutically acceptable carriers and excipients include sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as polyethylene glycol and propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate; coloring agents; releasing21 4882-8755-5522.2agents; coating agents; sweetening, flavoring and perfuming agents; preservatives; antioxidants; ion exchangers; alumina; aluminum stearate; lecithin; self-emulsifying drug delivery systems (SEDDS) such as d-atocopherol polyethyleneglycol 1000 succinate; surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices; serum proteins such as human serum albumin; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; cellulose- based substances; polyacrylates; waxes; and polyethylene-polyoxypropylene-block polymers. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds or compositions described herein.

[0058] It is understood that aspects and variation of the invention described herein include “consisting” and / or “consisting essentially of” aspects and variations. Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present disclosure that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present disclosure that consist essentially of, or consist of, the recited processing steps.

[0059] The term “including” is used to mean “including but not limited to.” “Including” and “including but not limited to” are used interchangeably. II. T cells and T cell receptors

[0060] T cells are a type of immune cell that can recognize and bind to antigens found on abnormal cells, cancer cells, cells from other organisms, or cells that have been infected by viruses or other pathogens. T cells primarily recognize foreign antigens displayed on the cell membrane of the individual’s own cells. The antigens are derived from pathogenic or cancer- related proteins, which are delivered to the cell surface by specialized glycoproteins called major histocompatibility complex molecules. T cells can be further distinguished by the class of MHC22 4882-8755-5522.2proteins they recognize. T cells expressing the CD4 effector protein bind to the MHC Class II molecule, while T cells expressing the CD8 effector protein bind to the MHC Class I molecules. Based on the type of T cell, the CD4 or CD8 molecules associate on the T-cell surface with T cell receptors, discussed below, and bind to invariant sites on the MHC part of the MHC:antigen complex, which then triggers the T cell to make an effective response. For instance, the CD8 effector protein binds to MHC class I molecules and allows the T cell receptors to bind to the upper part of the molecule .

[0061] T cells have receptors, termed T cell receptors (TCRs), on their surface. Each TCR is a heterodimer of two different polypeptide chains linked by a disulfide bond. The two known heterodimers are the αβ TCRs and the γδ TCRs. The chains of the TCR polypeptides include an amino-terminal variable (V) region that is similar to the immunoglobulin V domain, a constant (C) region which is similar to the immunoglobulin C domain, and a short hinge region that forms the interchain disulfide bond. The C region of the TCR polypeptide chains contain complementarity-determining regions that allow it to bind to portions of the MHC molecules.

[0062] Upon binding of the MHC:antigen complex by the effector proteins and TCRs of the T cell, the T cell can either destroy the cell expressing the MHC:antigen complex if it is a cytotoxic T cell or can activate other immune cells, including lymphocytes and macrophages, to target the cell if it is a helper T cell. Generally, helper T cells recognize MHC class II molecules, while cytotoxic T cells and regulatory T cells recognize MHC class I molecules. In addition to targeting cells for destruction, T cells can also release cytokines, which are molecules that mediate inflammation and regulate other immune cells. Cytokines are generally thought to be released by helper T cells. Cytokines may be grouped as chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors based on their structure and identity. Examples of such cytokines include but are not limited to IL-12, IL-15, IL-33, IL-25, IFNA2, and IFNW1. These cytokines can enhance cellular immune responses or enhance antibody responses.

[0063] Provided herein are T cell receptors (TCRs) that may be used to generate an anti-tumor response and reduce resistance to ICB treatment.

[0064] The T cell receptor (TCR) may be an αβ TCR. The αβ TCR may be encoded by the polynucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least23 4882-8755-5522.290%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the polynucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 24-46. Table 1: Exemplary αβ T Cell Receptor Nucleic Acid Sequences Identifier Sequence SEQ ID NO: 1 GCCACCATGGAGACCGACACGTTGCTCCTTTGGGTGTTGCTTCTGTGGGTACCCGGTTCCAC CGGTGATGCCGCTCAAAAGGTGACTCAGGCCCAGTCCAGCGTGTCTATGCCAGTGCGGAAA A C T C T C A A T C G C T A C G A C A T T G C A T A G A C G C T G24 4882-8755-5522.2ATGAGTGGACCCAGGATAGAGCCAAGCCAGTGACGCAGATTGTGTCCGCAGAGGCCTGGG GAAGAGCAGACTGTGGATTCACCAGTGTAAGCTACCAACAGGGTGTCCTTTCCGCTACCAT CCTGTATGAGATCCTGTTGGGCAAGGCTACCCTGTACGCAGTATTGGTGTCCGCCCTGGTTC G C T A T G G C C T C T A A G G G A T T A A G C T G A T A C A A T C T C G G T G C C C A T A C25 4882-8755-5522.2GGCGACACCTCTTGGGATACACGCCAGATGTTCTTTGGCACAGGGATCAAGCTGTTCGTGG AGCCGCGTTCCCAGCCGCATACCAAGCCCTCCGTTTTCGTCATGAAGAACGGCACCAACGT GGCATGCCTGGTGAAGGAGTTCTACCCCAAGGACATTCGCATCAACCTGGTGTCAAGCAAA A C G G T T T G G T T A G T A G A C C A C C G G G A G G A G C C A G T C T C T G T T G C G A C TC G A26 4882-8755-5522.2ATTCTTCTGCTTAAAGTCGCGGGATTCAATTTACTTATGACCCTCAGATTATGGTCAAGCTA A SEQ ID NO: 6 GCCACCATGGAAACGGACACCCTGTTGCTGTGGGTCTTGCTGTTGTGGGTGCCTGGAAGCA G A A A G A T C G T T T T G A T G G C A T T C A T G C G G G G C G A T C C A C A G C G C T C27 4882-8755-5522.2GTGACTGTGAGGGCTAACATCCAGAACCCGGATCCCGCCGTCTACCAGCTGCGGGACAGCA AGTCATCTGACAAGTCTGTGTGCCTGTTTACAGATTTCGACAGCCAGACCAACGTGAGTCA GTCCAAGGATTCAGACGTCTACATCACCGATAAGACTGTGCTGGATATGCGGTCCATGGAC T T T C A C C G G T A T C T A A G G T G T G C A G C G C G G G T G T C A C A C G T28 4882-8755-5522.2GGCCTCATCCGAAGGTGCTGTGGTTGAAATCTTCTGCAACCACTCCGTGAGCAACGCTTATA ATTTCTTTTGGTATCTGCATTTCCCCGGATGCGCACCCCGCCTCCTGGTCAAGGGCTCCAAG CCTTCCCAACAGGGACGCTACAATATGACTTATGAACGTTTTTCCAGCTCCCTTCTCATCCT G C G T C G A A G G T T C A G T G A G C C G T T A C T T A C C G G G C A T G C A G A29 4882-8755-5522.2ATTCTGTACGAAATCCTGCTCGGTAAGGCCACCTTGTATGCTGTGCTGGTCAGCGCCCTCGT GCTTATGGCAATGGTTAAGAGGAAAGACAGCCGCGGAGGCTCCGGTGCTACCAACTTCAGC CTCCTGAAGCAGGCGGGCGACGTCGAAGAGAATCCAGGGCCGATGGAGACCGACACCCTC C T G T C C G A T C G T C G T C G C C A G A C C T A C A T T G G C C A A G C C C C C C A G C C C30 4882-8755-5522.2TTTCCACCTGAAGTGGCGGTATTCGAACCCAGCGAGGCCGAAATAAGCCATACGCAGAAAG CAACTCTCGTCTGTTTGGCTACCGGATTTTATCCGGATCATGTCGAACTTTCTTGGTGGGTTA ACGGAAAAGAAGTTCATAGCGGAGTATCAACTGATCCCCAACCACTGAAAGAACAACCAG A G C T C T C G A C T G C A A T T T C G C A C G G C T G T T C C A A T A T T T G C T C A31 4882-8755-5522.2ACAAGAAGTCACTGAAGTGCGAGCAGCACATGGGCCATCGCGCAATGTACTGGTATAAAC AAAAGGCCAAGAAGCCCCCTGAATTGATGTTCGTGTATTCTTACGAAAAGTTGTCAATCAA CGAGAGCGTACCCAGCCGTTTTAGCCCGGAGTGTCCAAATTCCTCATTGTTGAATCTGCATC A C T G A G T A G A G A G C C A T C T A T T C G T G G G C C G T A C C A C G C A C T T32 4882-8755-5522.2AGTATCATCCCTGAGGATACATTCTTTCCTTCTCCTGAGTCTTCTTGCGACGTGAAACTTGTG GAAAAGTCCTTCGAGACCGACACAAATCTTAATTTCCAGAATCTCAGCGTCATCGGATTTA GAATTCTTCTGTTGAAGGTTGCTGGATTCAATCTCTTGATGACACTCCGTCTTTGGAGTAGTT A C G A A G T T A T G C C A G C G A A T G C T T T T C C A A A T T G G A G T T A T C A C T T33 4882-8755-5522.2TCAGAAAGCCCGCAAGTCTGCTAATTTGGTGATAAGTGCATCCCAGCTCGGAGATTCCGCC ATGTATTTCTGCGCCATGTCATTGTTTGAAACCGGCGCCAATAATTTGTTCTTCGGCACCGG CACCCGCCTTACTGTGATCCCTTACATTCAAAATCCGGATCCCGCAGTATATCAACTTCGCG T A T A A A C T C T T A T A A C A G T G C A G A T A A T A A C T A T G A C G C T T T T34 4882-8755-5522.2TTGAAACAAGCTGGGGATGTCGAAGAAAATCCAGGGCCAATGGAGACTGACACACTTCTTC TTTGGGTTCTTCTGCTTTGGGTGCCAGGAAGCACAGGAGATGCAGAGGATCAAGTCACCCA ATCCCCTGAAGCGCTCAGGCTGCAAGAAGGCGAATCTTCATCACTGAATTGTTCATATACC T C T C T A T T T C C C A G C C C G A T A T A C C A C C C C T A T A A G A C A G G T A A G C G35 4882-8755-5522.2CAAAATCCAAGAAATCATTTTCGATGCCAGGTGCAATTTTATGGACTGTCTGAAAACGATG AATGGACTCAAGACAGAGCAAAGCCCGTAACACAAATTGTGTCTGCTGAAGCTTGGGGCCG AGCGGATTGCGGTTTTACATCTGAAAGCTATCAACAGGGAGTTCTTTCAGCGACTATTTTGT G A G C C C G T A T T A C G T C G T G C G G G T A T T A G G T T C T A C A TTable 2: Exemplary αβ T Cell Receptor Amino Acid Sequences Identifier Sequence36 4882-8755-5522.2SEQ ID NO: 24 ATMETDTLLLWVLLLWVPGSTGDAAQKVTQAQSSVSMPVRKAVTLNCLYETSWWSYYIF WYKQLPSKEMIFLIRQGSDEQNAKSGRYSVNFKKAAKSVALTISALQLEDSAKYFCALGTGH PLFLLFSYWGAPDKLIFGKGTRVTVEPRSQPHTKPSVFVMKNGTNVACLVKEFYPKDIRINL K A T Q T H A D L Q T S IP E N W H A S N IT T K IT T K L R S V E M P K S Q NS V E M37 4882-8755-5522.2AMVKRKDSRGGSGATNFSLLKQAGDVEENPGPMETDTLLLWVLLLWVPGSTGDAGENVEQ HPSTLSVQEGDSAVIKCTYSDSASNYFPWYKQELGKGPQLIIDIRSNVGEKKDQRIAVTLNKT AKHFSLHITETQPEDSAVYFCAASHGSSNTGKLIFGQGTTLQVKPDIQNPDPAVYQLRDSKSS Y R N V Q N Q A R E N W H A V E W G D L Q S L T E N W H A V E W P S S A A V D38 4882-8755-5522.2FACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMT LRLWSS SEQ ID NO: 35 ATMETDTLLLWVLLLWVPGSTGDAAIELVPEHQTVPVSIGVPATLRCSMKGEAIGNYYINW Q P S D S A D Q A T N W H A K II R Q W D V N K II W G EL L A A R V D T D V E M P G K II Q39 4882-8755-5522.2AYEQYFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWV NGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDE WTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLM Q S QS W D IT L L C L V S A A S G V E M Q K S T T M P E C D G W D V D40 4882-8755-5522.2KSSGRSTLYIAASQPGDSATYLCAVRTLGSGGYNKLIFGAGTRLAVHPYIQNPDPAVYQLRD SKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACAN AFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS D FF V R R G I D Py y q , , least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at41 4882-8755-5522.2least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840.

[0066] The αβ TCR may have the specific combination of α TCR chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of42 4882-8755-5522.2SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α43 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an44 4882-8755-5522.2amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of45 4882-8755-5522.2SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α46 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5. Table 3: Exemplary αβ T Cell Receptor α Chain and β Chain Nucleic Acid Sequences Identifier α Chain Sequence Identifier β Chain Sequence SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT G C G T A G G G C G T G T C T C G T C T C T47 4882-8755-5522.2CCTGTGATGTCAAGCTGGTCGAGA GGCAGAACCCCCGCAACCACTTCC AAAGCTTTGAAACAGATACGAACC GCTGTCAAGTCCAGTTCTACGGGCT TAAACTTTCAAAACCTGTCAGTGAT CTCGGAGAATGACGAGTGGACCCA A G T C T T G C T G T T A T T A G T C A G C G G A G G G T T C G A G T A T C T G C G48 4882-8755-5522.2CTGTTATCAAGTGTACTTATTCAGA ACAGCGAGTGACGCTGAGATGCTC CAGTGCCTCAAACTACTTCCCTTGG CCCTAGGTCTGGAGACCTCTCTGTG TATAAGCAAGAACTTGGAAAAGGA TACTGGTACCAACAGAGCCTGGAC T A T T A C G A A T C G G A G A A A G T C T C G C C G C T A T A A C T T T T A C G C G G A T49 4882-8755-5522.2TGTGTATATCACAGACAAAACTGT TCTTCCCCGACCACGTGGAGCTGA GCTAGACATGAGGTCTATGGACTT GCTGGTGGGTGAATGGGAAGGAGG CAAGAGCAACAGTGCTGTGGCCTG TGCACAGTGGGGTCAGCACGGACC G T C A C G C G C G A C C T G A G G C C G A A A G A G C A G G A T A G C G T C A C G T G C G A C C50 4882-8755-5522.2CTCGTGCTGATGGCCATGGTCAAG AGAAAGGATTCCAGAGGC SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT G C C A T A T T T C T C C C A T T T G A A T G C A C G C C C G G T T G T G C G C G C T A T T A51 4882-8755-5522.2GACCATTTATAACCAGGGAGGAAA TTTCTGTGCCAGCAGCAGAGGCAC GCTTATCTTCGGACAGGGAACGGA CAACACCGGGGAGCTGTTTTTTGG GTTATCTGTGAAACCCAATATCCA AGAAGGCTCTAGGCTGACCGTACT C C T A A T A C T G T C A G T T G C T G C C A G T T G C T C T T C G G G G C G C G G C52 4882-8755-5522.2CCTGTCAGTGATTGGGTTCCGAATC TCGGAGAATGACGAGTGGACCCAG CTCCTCCTGAAAGTGGCCGGGTTTA GATAGGGCCAAACCTGTCACCCAG ATCTGCTCATGACGCTGCGGCTGTG ATCGTCAGCGCCGAGGCCTGGGGT C G T G T A T G C C A T A T T T C T G G C A G G A T A G C G T C A C G T G C G A C C T G A G G53 4882-8755-5522.2TACAACCTCCAGTGGTTTAGGCAG GGAGACCTCTCTGTGTACTGGTACC GACCCTGGGAAAGGTCTCACATCT AACAGAGCCTGGACCAGGGCCTCC CTGTTGCTTATTCAGTCAAGTCAGA AGTTCCTCATTCAGTATTATAATGG A A A G A C A T T C C G G G C C G C T G C G G A C C G A C T G T G C G A T A T G G G A A G G A T A G54 4882-8755-5522.2CAAGAGCAACAGTGCTGTGGCCTG TGCACAGTGGGGTCAGCACAGACC GAGCAACAAATCTGACTTTGCATG CGCAGCCCCTCAAGGAGCAGCCCG TGCAAACGCCTTCAACAACAGCAT CCCTCAATGACTCCAGATACTGCCT C A C G T G C G A C C T G C G C T G A A G G T A C G C C C G G C C C C T C A T G T C G T C55 4882-8755-5522.2SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT 59 GGGTGCTGTTGCTGTGGGTACCTG 166 TGCTGTTGTGGGTGCTGTTGCTGTG GTTCTACCGGTGACGCCGCCCAGT GGTACCTGGTTCTACCGGTGACGC G A T A A C C A G C A C T G A T T C C C A C A G T C T T C C T G C G T A G G G C C56 4882-8755-5522.2TCTGTGAAACCCAATATCCAGAAC TTCGGGCCAGGGACACGGCTCACC CCTGACCCTGCCGTGTACCAGCTG GTGCTAGAGGACCTGAAAAACGTG AGAGACTCTAAATCCAGTGACAAG TTCCCACCCGAGGTCGCTGTGTTTG C T G G C G C G G C G G T C G T G T A T G C G T A G G G C G C A C G C G A G G C57 4882-8755-5522.2GCCGGGTTTAATCTGCTCATGACGC AGCGCCGAGGCCTGGGGTAGAGCA TGCGGCTGTGGTCCAGCTAA GACTGTGGCTTCACCTCCGAGTCTT ACCAGCAAGGGGTCCTGTCTGCCA G G T G C G C G C T A T T A G C C G G C T G G C G C G G C G G T C G T G T A T G C C T A58 4882-8755-5522.2CCAGTTGCTGACGTATATTTTTTCA CACCTCATCCACTATTCCTATGGAG AATATGGACATGAAACAAGACCAA TTAATTCCACAGAGAAGGGAGATC AGACTCACTGTTCTATTGAATAAA TTTCCTCTGAGTCAACAGTCTCCAG T C C T G T T G C G G C A G C C C C G C C A T T A C T A T G T A T T T A C C T T G G C T A T G T A59 4882-8755-5522.2GCCTGGAGCAACAAATCTGACTTT CTCCAGATACTGCCTGAGCAGCCG GCATGTGCAAACGCCTTCAACAAC CCTGAGGGTCTCGGCCACCTTCTGG AGCATTATTCCAGAAGACACCTTCT CAGAACCCCCGCAACCACTTCCGC T G A A T C G T C T G A T T A G C A A G T A C C C G G C C C C T C A T G T C G T C C T60 4882-8755-5522.2TCAGTGGTCAACAGCTGAATCAGA GGGGGCAGAACTCTCAGAAGCTGA GTCCTCAATCTATGTTTATCCAGGA AGTTGCCCAGTCCCCCAGATATAA AGGAGAAGATGTCTCCATGAACTG GATTACAGAGAAAAGCCAGGCTGT T C G A T C T T C C C C C G G C C C C T C A T G T C G T C C T G T G C G A T C A G G T G C61 4882-8755-5522.2TCTAAATCCAGTGACAAGTCTGTCT GCTGTGTTTGAGCCATCAGAAGCA GCCTATTCACCGATTTTGATTCTCA GAGATCTCCCACACCCAAAAGGCC AACAAATGTGTCACAAAGTAAGGA ACACTGGTGTGCCTGGCCACAGGC G C C G C T G C G A C C G T T T C G A C T A T C C G G C A C G C G A G G C A T62 4882-8755-5522.2ACCAGCAAGGGGTCCTGTCTGCCA CCATCCTCTATGAGATCTTGCTAGG GAAGGCCACCTTGTATGCCGTGCT G C T A T A A C T T T T A C T G C A C C G C C G C T G C G A C C G C T C G G A A G C63 4882-8755-5522.2CCAGTATGTTTCTCTGCTCATCAGA TCCAGACAAAGCTCACTTAAATCTT GACTCCCAGCCCAGTGATTCAGCC CACATCAATTCCCTGGAGCTTGGTG ACCTACCTCTGTGCCGTGAGAGGC ACTCTGCTGTGTATTTCTGTGCCAG G T G C A C C G C C G C T G C G A C C G C G A T T C G C A G C G A G C G G A G G G T T C64 4882-8755-5522.2TGTGATGTCAAGCTGGTCGAGAAA GCAACCACTTCCGCTGTCAAGTCC AGCTTTGAAACAGATACGAACCTA AGTTCTACGGGCTCTCGGAGAATG AACTTTCAAAACCTGTCAGTGATTG ACGAGTGGACCCAGGATAGGGCCA G T A T C C T G T C G A C A C A T A A C A C A T C T C C C C A T G T A A T T65 4882-8755-5522.2AGTGCTTTTCAATACTTCATGTGGT AATCACTTATACTTCTATTGGTACA ACAGACAGTATTCCAGAAAAGGCC GACAAATCTTGGGGCAGAAAGTCG CTGAGTTGCTGATGTACACATACTC AGTTTCTGGTTTCCTTTTATAATAA T A G C A G C A C G C G A G G C A T A G G TT G A G A G A T A T C G G C A G G A T A66 4882-8755-5522.2CTATGGACTTCAAGAGCAACAGTG GCTGGTGGGTGAATGGGAAGGAGG CTGTGGCCTGGAGCAACAAATCTG TGCACAGTGGGGTCAGCACAGACC ACTTTGCATGTGCAAACGCCTTCAA CGCAGCCCCTCAAGGAGCAGCCCG T C A C G T G C G A C C T T G G A C C G A T G T T C T T C G G G G C G C G G C G G T G C G T A67 4882-8755-5522.2SEQ ID NO: ATGAGGCAAGTGGCGAGAGTGATC SEQ ID NO: CCGCCACCATGGGCCCTGGGCTCC 76 GTGTTCCTGACCCTGAGTACTTTGA 183 TCTGCTGGGTGCTGCTTTGTCTCCT GCCTTGCTAAGACCACCCAGCCCA GGGAGCAGGCTCAGTGGAGACTGG T T T C C G C C T A C A C C G G A G G A G T T C G A G T A T C C T G A G G C C G A A A G A C A T68 4882-8755-5522.2AGACTCTAAATCCAGTGACAAGTC GAACAAGGTGTTCCCACCCGAGGT TGTCTGCCTATTCACCGATTTTGAT CGCTGTGTTTGAGCCATCAGAAGC TCTCAAACAAATGTGTCACAAAGT AGAGATCTCCCACACCCAAAAGGC G G G C C G C T G C G G A C C G A T G C G A G C C G C T C G C A C C G C C G C T G C G A69 4882-8755-5522.2AGGGGTCCTGTCTGCCACCATCCTC TATGAGATCTTGCTAGGGAAGGCC ACCTTGTATGCCGTGCTGGTCAGTG C T G T T T T A A C C C T C G C A C C A G C G T C A C G C G C G A C C T G C C T A G C G T70 4882-8755-5522.2GATCTCAGACTCACAGCTGGGGGA GACCCTGGAGTCTGCCAGGCCCTC TGCCGCGATGTATTTCTGTGCTTAT ACATACCTCTCAGTACCTCTGTGCC AAGGGCGGATCTGAAAAGCTGGTC AGCAGTGAGAGCGGCGACAGAGCC C G C A C C G C C G C T G C G A C C G C T G T G A T C A G C G T T G T C A C G C G A G71 4882-8755-5522.2AGCTTTGAAACAGATACGAACCTA GTCCAGTTCTACGGGCTCTCGGAG AACTTTCAAAACCTGTCAGTGATTG AATGACGAGTGGACCCAGGATAGG GGTTCCGAATCCTCCTCCTGAAAGT GCCAAACCCGTCACCCAGATCGTC A T A G C C G T T A T A C C T G C G G A G G A G T T C G A G T A T C C T A A T T A72 4882-8755-5522.2CCCCAACCAAGGACTCCAGCTTCT GACAAATCTTGGGGCAGAAAGTCG CCTGAAGTATTTATCAGGATCCACC AGTTTCTGGTTTCCTTTTATAATAA CTGGTTGAAAGCATCAACGGTTTT TGAAATCTCAGAGAAGTCTGAAAT A G C G C G G A G G A G T T C G A G T A T C C T A A T T A G A T A G G G C A C G C73 4882-8755-5522.2GCCTGGAGCAACAAATCTGACTTT ACAGACCCGCAGCCCCTCAAGGAG GCATGTGCAAACGCCTTCAACAAC CAGCCCGCCCTCAATGACTCCAGA AGCATTATTCCAGAAGACACCTTCT TACTGCCTGAGCAGCCGCCTGAGG G C A T A G G T G A G G G A G G T G G A G G G A A A A C T G C C T C C C C A A C C74 4882-8755-5522.2SEQ ID NO: ATGATGAAATCCTTGAGAGTTTTAC SEQ ID NO: CCGCCACCATGAGCAACCAGGTGC 86 TGGTGATCCTGTGGCTTCAGTTAAG 193 TCTGCTGTGTGGTCCTTTGTTTCCT CTGGGTTTGGAGCCAACAGAAGGA GGGAGCAAACACCGTGGATGGTGG T T A T A C C T G C C G G A G G A G T T C G A G T A T C C T T T C G A C T A T C C C75 4882-8755-5522.2ACCAGCTGAGAGACTCTAAATCCA ACCAGGCTCACGGTCACAGAGGAC GTGACAAGTCTGTCTGCCTATTCAC CTGAAAAACGTGTTCCCACCCGAG CGATTTTGATTCTCAAACAAATGTG GTCGCTGTGTTTGAGCCATCAGAA G A G G A G T T C G A G T A T C C T T T C G A C T A T C C C C G G A G G A G T T C G A G76 4882-8755-5522.2ATCTGCTCATGACGCTGCGGCTGTG CCGAGGCCTGGGGTAGAGCAGACT GTCCAGCTAA GTGGCTTCACCTCCGAGTCTTACCA GCAAGGGGTCCTGTCTGCCACCAT C C TT G A G A G A T A T C G C A T T C C G G G C C G C T G C G G A C C G A T T T C G A C77 4882-8755-5522.2TACAGCACAGCTCAATAAAGCCAG CAAGGCCACATACGAGCAAGGCGT CCAGTATGTTTCTCTGCTCATCAGA CGAGAAGGACAAGTTTCTCATCAA GACTCCCAGCCCAGTGATTCAGCC CCATGCAAGCCTGACCTTGTCCACT C C C G C C A C G G C G A G G C A T A G C C T A T A A C T T T T A C G G A G A T T C C C78 4882-8755-5522.2ATTCCAGAAGACACCTTCTTCCCCA GCAGCCGCCTGAGGGTCTCGGCCA GCCCAGAAAGTTCCTGTGATGTCA CCTTCTGGCAGAACCCCCGCAACC AGCTGGTCGAGAAAAGCTTTGAAA ACTTCCGCTGTCAAGTCCAGTTCTA G T C T G T C C A C T G T T T C C G C C T A C C C G C A C C G C C G C T G C G A C C G C T G79 4882-8755-5522.2GAGCTGCAAACCTGCCTTGTAATC GATCAAAACGAGAGGACAGCAAGT ACTCTACCATCAGTGGAAATGAGT GACACTGAGCTGCTCCCCTATCTCT ATGTGTATTGGTATCGACAGATTCA GGGCATAGGAGTGTATCCTGGTAC T G C C T G C G G C A C G C G A G G C A T A G G T G A G G C C G A A A G A C A T T C C80 4882-8755-5522.2TTTGATTCTCAAACAAATGTGTCAC CACACTGGTGTGCCTGGCCACAGG AAAGTAAGGATTCTGATGTGTATA CTTCTTCCCCGACCACGTGGAGCTG TCACAGACAAAACTGTGCTAGACA AGCTGGTGGGTGAATGGGAAGGAG C C G C T G C G G A C C G A C T G T G C G A T A T G G G A A G G A T A G C G T C A C G T G C G A C C81 4882-8755-5522.2CTCGTGCTGATGGCCATGGTCAAG AGAAAGGATTCCAGAGGC SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT G C G T T G C A C G G T T T C C G G G C C G C T G C G G A C C G A T G C G C G C T A T T A82 4882-8755-5522.2TGGAGCCGGAACCACAGTAACTGT CGGCGAGGTGGAGCAGTTCTTCGG AAGAGCAAATATCCAGAACCCTGA GCCAGGGACACGGCTCACCGTGCT CCCTGCCGTGTACCAGCTGAGAGA AGAGGACCTGAAAAACGTGTTCCC C T A A T A C T G T C A G T T G C T G C G T A G G G C G A A G G A T A G C G T C A C G83 4882-8755-5522.2ACCTGTCAGTGATTGGGTTCCGAAT TGGACCCAGGATAGGGCCAAACCT CCTCCTCCTGAAAGTGGCCGGGTTT GTCACCCAGATCGTCAGCGCCGAG AATCTGCTCATGACGCTGCGGCTGT GCCTGGGGTAGAGCAGACTGTGGC G A C C T G C G T T C T G T T C T C G G A G A T T C C C A C A G T C T G T C C A T G C A T84 4882-8755-5522.2TTTAGGCAGGACCCTGGGAAAGGT TATTGGTACCGACAGGCCCTGGGG CTCACATCTCTGTTGCTTATTCAGT CAGGGCCCAGAGTTTCTGACTTACT CAAGTCAGAGAGAGCAAACAAGTG TCAATTATGAAGCCCAACAAGACA T T G T C A G A T C G G A G A A A G T C T C G C C G T G C G C T G G G G A G A A A C A85 4882-8755-5522.2TATGGACTTCAAGAGCAACAGTGC GGAGGTGCACAGTGGGGTCAGCAC TGTGGCCTGGAGCAACAAATCTGA GGACCCGCAGCCCCTCAAGGAGCA CTTTGCATGTGCAAACGCCTTCAAC GCCCGCCCTCAATGACTCCAGATA T C T C C C C A T G T G G A T A A C C A G C G G A G A T T C C C A C A G T C T G T C C A86 4882-8755-5522.2SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT 103 GGGTGCTGTTGCTGTGGGTACCTG 210 TGCTGTTGTGGGTGCTGTTGCTGTG GTTCTACCGGTGACGCCAAGGACC GGTACCTGGTTCTACCGGTGACGC C C A T A T T T C T G T C C T A T A C T G T C A T T T G C T G C C A T A T T T C T G C87 4882-8755-5522.2AACCCTGACCCTGCCGTGTACCAG TGGAGGACCTGAAAAACGTGTTCC CTGAGAGACTCTAAATCCAGTGAC CACCCGAGGTCGCTGTGTTTGAGC AAGTCTGTCTGCCTATTCACCGATT CATCAGAAGCAGAGATCTCCCACA C A G A T C T C A T G T C G T C T G G A T A T T C C T G T G T A A G T G T A G G C T G A A88 4882-8755-5522.2GCTCATGACGCTGCGGCTGTGGTC GAGCAGACTGTGGCTTCACCTCCG CAGCTAA AGTCTTACCAGCAAGGGGTCCTGT CTGCCACCATCCTCTATGAGATCTT C G T T G C G A T G T A T T G T T T A G C G G C C C C T C A T G C G T A T T G C C T A89 4882-8755-5522.2GAAGCTTATAAGCAACAGAATGCA CTTCCGCAACCGGGCTCCTCTAGAT ACAGAGAATCGTTTCTCTGTGAACT GATTCGGGGATGCCGAAGGATCGA TCCAGAAAGCAGCCAAATCCTTCA TTCTCAGCAGAGATGCCTGATGCA T G T G T A A G C G G C C C C T C A T G C G T A T T G T A T T A T T G G G C C C T A A T A90 4882-8755-5522.2ATCTGACTTTGCATGTGCAAACGCC GGAGCAGCCCGCCCTCAATGACTC TTCAACAACAGCATTATTCCAGAA CAGATACTGCCTGAGCAGCCGCCT GACACCTTCTTCCCCAGCCCAGAA GAGGGTCTCGGCCACCTTCTGGCA G T C A G T T G C T G A C G C G A C G C T A G C A C G C G A G G C A T A G C T G91 4882-8755-5522.2GTTCTACCGGTGACGCCCTTGCTAA GGTACCTGGTTCTACCGGTGACGC GACCACCCAGCCCATCTCCATGGA CGAGACTGGAGTCACCCAAAGTCC CTCATATGAAGGACAAGAAGTGAA CACACACCTGATCAAAACGAGAGG C G T T A C C T C G C C C G G C C C C T C A T G T C G T C T G C G C G C T A T T A T C C92 4882-8755-5522.2AATCCAGTGACAAGTCTGTCTGCCT CCACCCGAGGTCGCTGTGTTTGAG ATTCACCGATTTTGATTCTCAAACA CCATCAGAAGCAGAGATCTCCCAC AATGTGTCACAAAGTAAGGATTCT ACCCAAAAGGCCACACTGGTGTGC C A G A T C T C A T G C G T A T T G C G C G C T A T T A T C C C C C A G A T C T C A T G93 4882-8755-5522.2GCTCATGACGCTGCGGCTGTGGTC GTCCTACCAGCAAGGGGTCCTGTC CAGCTAA TGCCACCATCCTCTATGAGATCCTG CTAGGGAAGGCCACCCTGTATGCT A T T G G T C C G C T C G C A C C G C C G C T G C G A C C G T G G A T94 4882-8755-5522.2TTACAGCACAGCTCAATAGAGCCA TGATTCAGGGATGCCCGAGGATCG GCCAGTATATTTCCCTGCTCATCAG ATTCTCAGCTAAGATGCCTAATGC AGACTCCAAGCTCAGTGATTCAGC ATCATTCTCCACTCTGAAGATCCAG T A T C G T C T C G T C T C T C T A A G T C C G T G C G C T G A A G G T A C G C C C G G C C95 4882-8755-5522.2GTGCAAACGCCTTCAACAACAGCA TCCAGATACTGCCTGAGCAGCCGC TTATTCCAGAAGACACCTTCTTCCC CTGAGGGTCTCGGCCACCTTCTGGC CAGCCCAGAAAGTTCCTGTGATGT AGAACCCCCGCAACCACTTCCGCT C A T G T C G T C T G G A T T T A G A C G C C A C A G A T C T C A T G T C G T C T G96 4882-8755-5522.2GTTCTACCGGTGACGCCCGGAAGG GGTACCTGGTTCTACCGGTGACGC AGGTGGAGCAGGATCCTGGACCCT CGGAGCTGGAGTCTCCCAGTCCCC TCAATGTTCCAGAGGGAGCCACTG CAGTAACAAGGTCACAGAGAAGGG A T G T A T T G T C A A T C G G A G A A A G T C T C G C C G T G C G A T G A A A G C A T G T97 4882-8755-5522.2GAGAGACTCTAAATCCAGTGACAA TCCCACCCGAGGTCGCTGTGTTTGA GTCTGTCTGCCTATTCACCGATTTT GCCATCAGAAGCAGAGATCTCCCA GATTCTCAAACAAATGTGTCACAA CACCCAAAAGGCCACACTGGTGTG T G T A G G C T G A A T T C G T T G C C A G T T G C T C T T C G G G G C G C G G C G G T C98 4882-8755-5522.2GAGTCTTACCAGCAAGGGGTCCTG TCTGCCACCATCCTCTATGAGATCT TGCTAGGGAAGGCCACCTTGTATG T A T G C G C T G A A G G T T T T A G C G G C C C C T C A T G C G T A T T G G A T A T99 4882-8755-5522.2GCTATGGCTTTGAAGCTGAATTTAA AAATGAAACAGTTCCAAATCGCTT CAAGAGCCAAACCTCCTTCCACCT CTCACCTAAATCTCCAGACAAAGC GAAGAAACCATCTGCCCTTGTGAG TCACTTAAATCTTCACATCAATTCC T T C T T C G G G G C G C G G C G G T G C G T A T G C G C G C T A T T A C G G C A C A A T A C100 4882-8755-5522.2ACAACAGCATTATTCCAGAAGACA CAGATACTGCCTGAGCAGCCGCCT CCTTCTTCCCCAGCCCAGAAAGTTC GAGGGTCTCGGCCACCTTCTGGCA CTGTGATGTCAAGCTGGTCGAGAA GAACCCCCGCAACCACTTCCGCTG G T C A T T T G C T G G A T A T T C C T G G G A A A A C T G C C T C C C C A A C C T G C101 4882-8755-5522.2CTCATATGAAGGACAAGAAGTGAA AAGACACCTGGTCATGGGAATGAC CATAACCTGTAGCCACAACAACAT AAATAAGAAGTCTTTGAAATGTGA TGCTACAAATGATTATATCACGTG ACAACATCTGGGTCATAACGCTAT A A T T C T C C C A T T T G A A T G C A C G C C C G G T T G T G C C A T A A T T C T A G C A G G102 4882-8755-5522.2ATTCTCAAACAAATGTGTCACAAA AGATCTCCCACACCCAAAAGGCCA GTAAGGATTCTGATGTGTATATCAC CACTGGTGTGCCTGGCCACAGGCT AGACAAAACTGTGCTAGACATGAG TCTACCCCGACCACGTGGAGCTGA G C G T C A C G T G C G A C C T G C G T T C T G T T C T A C A C G G C G A G G C A T A G103 4882-8755-5522.2GAAGGCCACCCTGTATGCTGTGCT GGTCAGCGCCCTTGTGTTGATGGCC ATGGTCAAGAGAAAGGATTTC T G C G C G C T A T T A G T T T A G T G T A G G C T G A A T T C G T T G C G C G C T A T T104 4882-8755-5522.2ACTCGGCTGTCTACTTCTGTGCAGC GGAGCTGGGGGACTCAGCTTTGTA AAGAGGCCACAACTATGGTCAGAA TTTCTGTGCCAGCAGCGTGGGCGG TTTTGTCTTTGGTCCCGGAACCAGA CAACTACGAGCAGTACTTCGGGCC A C A C G G A G G A G C A T A G G T G C G T T G C A C G G T G G C C A C A G A T C T105 4882-8755-5522.2AGCTGGTCGAGAAAAGCTTTGAAA GTCAAGTCCAGTTCTACGGGCTCTC CAGATACGAACCTAAACTTTCAAA GGAGAATGACGAGTGGACCCAGGA ACCTGTCAGTGATTGGGTTCCGAAT TAGGGCCAAACCTGTCACCCAGAT G T C G T C T G C C A T A A T T C T G C C A C T G A A T G C A C G C C T G G C T G T G G106 4882-8755-5522.2CTATTCTGAACTGTGACTATACTAA ACAGAGCATGACACTGCTGTGTGC CAGCATGTTTGATTATTTCCTATGG CCAGGATATGAACCATGAATACAT TACAAAAAATACCCTGCTGAAGGT GTACTGGTATCGACAAGACCCAGG C A A G A G T A T T C G C G C C C C G A A T A G A T T A T G C G C G C T A T T A C T C C T107 4882-8755-5522.2AAAGTAAGGATTCTGATGTGTATA GGCCACAGGCTTCTACCCCGACCA TCACAGACAAAACTGTGCTAGACA CGTGGAGCTGAGCTGGTGGGTGAA TGAGGTCTATGGACTTCAAGAGCA TGGGAAGGAGGTGCACAGTGGGGT A C T G T C A G T T G C T G G C T G A G C G T A T A A G C G G C C C C T C A T G C G T108 4882-8755-5522.2GTGCTGGTCAGCGCCCTTGTGTTGA TGGCCATGGTCAAGAGAAAGGATT TC T G G C T G A G C G T A T A A G C G G C C C C T C A T G C G T A T T G G C T G T A A G C109 4882-8755-5522.2TGGGGGACTCAGCAATGTACTTCT TGCTCCCTCCCAGACATCTGTGTAC GTGCAATGAGAGAGGGCGACGGCA TTCTGTGCCAGCAGTTACAGCAGA ACGACTACAAGCTCAGCTTTGGAG GGCGGCAATTCACCCCTCCACTTTG A C A C A A T A C T G T C A T T T G C T G C G T T G C A C G G T G T G T A A G T G T A G G C T110 4882-8755-5522.2TCAAAACCTGTCAGTGATTGGGTTC CGGAGAATGACGAGTGGACCCAGG CGAATCCTCCTCCTGAAAGTGGCC ATAGGGCCAAACCTGTCACCCAGA GGGTTTAATCTGCTCATGACGCTGC TCGTCAGCGCCGAGGCCTGGGGTA T T C G T T G C G C T G G G G A G G C C C T A A T A C T G T C A G T T G C T G G A T111 4882-8755-5522.2CAGTGCTTTTCAATACTTCATGTGG TCCCTGGACTTTCAGGCCACAACTA TACAGACAGTATTCCAGAAAAGGC TGTTTTGGTATCGTCAGTTCCCGAA CCTGAGTTGCTGATGTACACATACT ACAGAGTCTCATGCTGATGGCAAC C A G C C T G C C A C G G C G A G G C A T A G C T G G C T G A G C G T C C C C A112 4882-8755-5522.2CTATGGACTTCAAGAGCAACAGTG ATGGGAAGGAGGTGCACAGTGGGG CTGTGGCCTGGAGCAACAAATCTG TCAGCACGGACCCGCAGCCCCTCA ACTTTGCATGTGCAAACGCCTTCAA AGGAGCAGCCCGCCCTCAATGACT C T C A T G C G T A T T G C G A T G A A A G C C C C A C A G A T C T C A T G T C G T113 4882-8755-5522.2GGCCATGGTCAAGAGAAAGGATTC CAGAGGC SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT G C G C T G A A G G T A C C A C A G A T C T C A T G T C G T C T G C G A T G A A A G C114 4882-8755-5522.2GTGCAATGAGCGTGTACAACACCG TATCTCTGTGCCAGTGGCCCCGGCC ACAAGCTTATCTTCGGACAGGGAA AGGCCGTGTACGAGCAGTACTTCG CGGAGTTATCTGTGAAACCCAATA GGCCGGGCACCAGGCTCACGGTCA C A C A G A T C T C A T G T C G T C T G G A T A A C C A G C G C C T T G C G G C A G C C115 4882-8755-5522.2AACTTTCAAAACCTGTCAGTGATTG CTCTCGGAGAATGACGAGTGGACC GGTTCCGAATCCTCCTCCTGAAAGT CAGGATAGGGCCAAACCTGTCACC GGCCGGGTTTAATCTGCTCATGAC CAGATCGTCAGCGCCGAGGCCTGG C C A T A T G G A T A A C C A G C G C C T T G C G G C A G C C C C G C C A T A T G C C A116 4882-8755-5522.2CCGAGGTTCCCAGTCCTTCTTCTGG ACAACATATGGGGCACAGGGCTAT TACAGACAATATTCTGGGAAAAGC GTATTGGTACAAGCAGAAAGCTAA CCTGAGTTGATAATGTTCATATACT GAAGCCACCGGAGCTCATGTTTGT T T C T C C G C C A C G G A G G A G C A T A G G T G C G C G A C C C T T G T G T C T C117 4882-8755-5522.2ATCACAGACAAAACTGTGCTAGAC GACCACGTGGAGCTGAGCTGGTGG ATGAGGTCTATGGACTTCAAGAGC GTGAATGGGAAGGAGGTGCACAGT AACAGTGCTGTGGCCTGGAGCAAC GGGGTCAGCACAGACCCGCAGCCC T C T C T A A G T C C G T G C G A T G T A T T G T T T T A G T G T A G G C T G A A T T C G118 4882-8755-5522.2ATGGCCATGGTCAAGAGAAAGGAT TCCAGAGGC SEQ ID NO: ATGGAAACCGATACCTTGCTGTTGT SEQ ID NO: CCGCCACCATGGAAACCGATACCT G G T C C G C C C G C T G A T T C C C A C A G T C T T C C T G C G C G C T A T T A119 4882-8755-5522.2CCAGCGGCTCCGGGTATGCACTCA TTTCTGTGCCAGCAGCGGCCCCGG ACTTCGGCAAAGGCACCTCGCTGT CACCGGCGGAAACACCATATATTT TGGTCACACCCCATATCCAGAACC TGGAGAGGGAAGTTGGCTCACTGT T A G C G G C C C C T C A T G C G T A T T G C C A T A T T T C T G G C A G G A T A G C G T C A C120 4882-8755-5522.2CAGATACGAACCTAAACTTTCAAA TACGGGCTCTCGGAGAATGACGAG ACCTGTCAGTGATTGGGTTCCGAAT TGGACCCAGGATAGGGCCAAACCT CCTCCTCCTGAAAGTGGCCGGGTTT GTCACCCAGATCGTCAGCGCCGAG C G A C C T G G C T G C C G G A G T T T A G T G T A G G C T G A A T T C G T T G G A T121 4882-8755-5522.2GCTCCTCCACCTACTTATACTGGTA TCCCTGGACTTTCAGGCCACAACTA TAAGCAAGAACCTGGAGCAGGTCT TGTTTTGGTATCGTCAGTTCCCGAA CCAGTTGCTGACGTATATTTTTTCA ACAGAGTCTCATGCTGATGGCAAC C A G C A T G T A A G T G T A G G C T G A A T T C G T T G C G T C G T T C C G T C G C A C C122 4882-8755-5522.2TTCTGATGTGTATATCACAGACAA TTCTTCCCCGACCACGTGGAGCTGA AACTGTGCTAGACATGAGGTCTAT GCTGGTGGGTGAATGGGAAGGAGG GGACTTCAAGAGCAACAGTGCTGT TGCACAGTGGGGTCAGCACGGACC G T C A C G C G C G A C Ca e : xempary αβ e ecepor α an an β an mno c equences Identifier α Chain Sequence Identifier β Chain Sequence SEQ ID NO: METDTLLLWVLLLWVPGSTGDAGE SEQ ID NO: _ATMETDTLLLWVLLLWVPGSTGDA PI N L Q V L Q S V A L H P E Q R K Q L A R N N Y P E123 4882-8755-5522.2DKTVLDMRSMDFKSNSAVAWSNKS LSWWVNGKEVHSGVSTDPQPLKEQ DFACANAFNNSIIPEDTFFPSPESSCD PALNDSRYCLSSRLRVSATFWQNPR VKLVEKSFETDTNLNFQNLSVIGFRI NHFRCQVQFYGLSENDEWTQDRAK Q L M H Q E V P A Q A G D E S P A A H T L M A E F L G PE F P F T S V A R N N F P E Q R K Q124 4882-8755-5522.2GVLSATILYEILLGKATLYAVLVSAL VLMAMVKRKDSRG SEQ ID NO: METDTLLLWVLLLWVPGSTGDARK SEQ ID NO: ATMETDTLLLWVLLLWVPGSTGDA T Y L G V D L Q S V A E F L Q F A S S E G G D E S F S L P N G V S E K Y P E Q R K Q L A125 4882-8755-5522.2SDPSYGLFWYKQPSSGEMIFLIYQGS NMNHEYMSWYRQDPGLGLRQIYYS YDQQNATEGRYSLNFQKARKSANL MNVEVTDKGDVPEGYKVSRKEKRN VISASQLGDSAMYFCAMSLFETGAN FPLILESPSPNQTSLYFCASSLVQSSY A P P E L A L S T G PE F P F T S V A R N N F P E Q R K Q L A E F L Q F A S S E G A R N N E F126 4882-8755-5522.2KSSDKSVCLFTDFDSQTNVSQSKDSD EPSEAEISHTQKATLVCLATGFYPDH VYITDKTVLDMRSMDFKSNSAVAW VELSWWVNGKEVHSGVSTDPQPLK SNKSDFACANAFNNSIIPEDTFFPSPE EQPALNDSRYCLSSRLRVSATFWQN Y S D H N S G E N R QI A A Q F F P E Q R K Q L A R N N F P E Q R K Q L A PI N L T A P P127 4882-8755-5522.2ESSCDVKLVEKSFETDTNLNFQNLSV DRAKPVTQIVSAEAWGRADCGFTSE IGFRILLLKVAGFNLLMTLRLWSS* SYQQGVLSATILYEILLGKATLYAVL VSALVLMAMVKRKDSRG A PI D T E F P F T S V A D S E F H K N Y S A P F E V P A Q A A L S T T E F P F T S V128 4882-8755-5522.2SEQ ID NO: METDTLLLWVLLLWVPGSTGDAKD SEQ ID NO: _ATMETDTLLLWVLLLWVPGSTGDA 285 QVFQPSTVASSEGAVVEIFCNHSVSN 392 DTEVTQTPKHLVMGMTNKKSLKCE AYNFFWYLHFPGCAPRLLVKGSKPS QHMGHRAMYWYKQKAKKPPELMF L N A P V L A E F L I A P P E L A Q Y N G V D L Q S V A P G L L E V P A Q A A Q F L129 4882-8755-5522.2ISDSQLGDAAMYFCAYQGGSEKLVF ATLKIQPSEPRDSAVYFCASGSGTRH GKGTKLTVNPYIQNPDPAVYQLRDS YGYTFGSGTRLTVVEDLNKVFPPEV KSSDKSVCLFTDFDSQTNVSQSKDSD AVFEPSEAEISHTQKATLVCLATGFF Q T S V A D Q T E V D L Q S V A E S A F H K N Y S A Q R N Q E V P A Q A A R N N F H K130 4882-8755-5522.2CANAFNNSIIPEDTFFPSPESSCDVKL EQPALNDSRYCLSSRLRVSATFWQN VEKSFETDTNLNFQNLSVIGFRILLLK PRNHFRCQVQFYGLSENDEWTQDR VAGFNLLMTLRLWSS* AKPVTQIVSAEAWGRADCGFTSVSY S A R N N F H K N Y S A S Q L D P P E L A PI S A P P E L A S N Y A P P E131 4882-8755-5522.2SYQQGVLSATILYEILLGKATLYAVL VSALVLMAMVKRKDSRG SEQ ID NO: METDTLLLWVLLLWVPGSTGDAAQ SEQ ID NO: ATMETDTLLLWVLLLWVPGSTGDA I S E F H K N Y S A P G L Y P E Q R K Q L A S P E F H K N Y S A T Y L G V D L Q S V A132 4882-8755-5522.2ATPYLFWYVQSPGQGLQLLLKYFSG NMNHEYMSWYRQDPGLGLRQIYYS DTLVQGIKGFEAEFKRSQSSFNLRKP MNVEVTDKGDVPEGYKVSRKEKRN SVHWSDAAEYFCAVSNFGNEKLTFG FPLILESPSPNQTSLYFCASSPKGHPP F Q T S V A Q Y N N A P V L A R N N Y E V P A Q A A Q Y N Y P E Q R K Q L A E H T P133 4882-8755-5522.2VCLFTDFDSQTNVSQSKDSDVYITDK PEVAVFEPSEAEISHTQKATLVCLAT TVLDMRSMDFKSNSAVAWSNKSDF GFYPDHVELSWWVNGKEVHSGVST ACANAFNNSIIPEDTFFPSPESSCDVK DPQPLKEQPALNDSRYCLSSRLRVSA G A E H G P T T A G A I N T F E V P A Q A A R N N Q E V P A Q A A R N N F S L P N134 4882-8755-5522.2DVKLVEKSFETDTNLNFQNLSVIGFR VTQIVSAEAWGRADCGFTSESYQQG ILLLKVAGFNLLMTLRLWSS* VLSATILYEILLGKATLYAVLVSALV LMAMVKRKDSRG A Q F E P P E L A E H G P G P F T S V A Q S N L P G P F T S V A R N N F P E Q R K Q L135 4882-8755-5522.2SEQ ID NO: METDTLLLWVLLLWVPGSTGDAAQ SEQ ID NO: _ATMETDTLLLWVLLLWVPGSTGDA 315 KVTQAQTEISVVEKEDVTLDCVYET 422 NAGVTQTPKFQVLKTGQSMTLQCA RDTTYYLFWYKQPPSGELVFLIRRNS QDMNHNSMYWYRQDPGMGLRLIY R G E F P F T S V A R Y E F P F T S V A D S F N A P V L A Q F N A P P E L A P136 4882-8755-5522.2ISDSQLGDAAMYFCAYKGGSEKLVF LTLESARPSHTSQYLCASSESGDRAE GKGTKLTVNPYIQNPDPAVYQLRDS QYFGPGTRLTVTEDLKNVFPPEVAV KSSDKSVCLFTDFDSQTNVSQSKDSD FEPSEAEISHTQKATLVCLATGFYPD L Q S V A L S T V L Q S V A R F P F T S V A S P I V D L Q S V A S N N V D L137 4882-8755-5522.2NKSDFACANAFNNSIIPEDTFFPSPES KEQPALNDSRYCLSSRLRVSATFWQ SCDVKLVEKSFETDTNLNFQNLSVIG NPRNHFRCQVQFYGLSENDEWTQD FRILLLKVAGFNLLMTLRLWSS* RAKPVTQIVSAEAWGRADCGFTSES V A S P Y P P E L A L S T G V Y Q T S V A L S T G V Y Q T S V A E F L D P P E138 4882-8755-5522.2SYQQGVLSATILYEILLGKATLYAVL VSALVLMAMVKRKDSRG SEQ ID NO: METDTLLLWVLLLWVPGSTGDADA SEQ ID NO: ATMETDTLLLWVLLLWVPGSTGDA I S Y Q T S V A P G L E V D L Q S V A S Q L V L Q S V A R N N I F H K N Y S A E139 4882-8755-5522.2SDPSYGLFWYKQPSSGEMIFLIYQGS QHMGHRAMYWYKQKAKKPPELMF YDQQNATEGRYSLNFQKARKSANL VYSYEKLSINESVPSRFSPECPNSSLL VISASQLGDSAMYFCAMREAYGNN NLHLHALQPEDSALYLCASSRRGRQ F A S S E G A Y D A V Y Q T S V A L S T Y P P E L A I N K N V F Q T S V K D K E G E140 4882-8755-5522.2DSKSSDKSVCLFTDFDSQTNVSQSKD ISHTQKATLVCLATGFFPDHVELSW SDVYITDKTVLDMRSMDFKSNSAVA WVNGKEVHSGVSTDPQPLKEQPALN WSNKSDFACANAFNNSIIPEDTFFPSP DSRYCLSSRLRVSATFWQNPRNHFR QI A T E A Q E F H K N Y S E H V IQ E V D L Q S V S E TI F S L P N G V G S T L PP G D T141 4882-8755-5522.2EKSFETDTNLNFQNLSVIGFRILLLKV TQDRAKPVTQIVSAEAWGRADCGFT AGFNLLMTLRLWSS* SESYQQGVLSATILYEILLGKATLYA VLVSALVLMAMVKRKDSRG M H F P E Q R K Q L A G K N F S L P N G V G R L Y E V P A Q A G S I F P E Q R K Q L142 4882-8755-5522.2SEQ ID NO: MMKSLRVLLVILWLQLSWVWSQQK SEQ ID NO: _ATMDTWLVCWAIFSLLKAGLTEPE 345 EVEQDPGPLSVPEGAIVSLNCTYSNS 452 VTQTPSHQVTQMGQEVILRCVPISNH AFQYFMWYRQYSRKGPELLMYTYS LYFYWYRQILGQKVEFLVSFYNNEIS T G E S A H T L M G H P Q P A A H T L M Q N S S R S D C V T G H E A G E S A H T L M G D E S143 4882-8755-5522.2YCIGASNYQLIWGAGTKLIIKPDIQNP LELGDSALYFCASSVGGGDGQPQHF DPAVYQLRDSKSSDKSVCLFTDFDS GDGTRLSILEDLNKVFPPEVAVFEPS QTNVSQSKDSDVYITDKTVLDMRSM EAEISHTQKATLVCLATGFFPDHVEL P N G V PS W G D R D C V T S L A F H K N Y S D H N S P A A H T L M G K K RI F P E Q144 4882-8755-5522.2SDFACANAFNNSIIPEDTFFPSPESSC PALNDSRYCLSSRLRVSATFWQNPR DVKLVEKSFETDTNLNFQNLSVIGFR NHFRCQVQFYGLSENDEWTQDRAK ILLLKVAGFNLLMTLRLWSS* PVTQIVSAEAWGRADCGFTSVSYQQ L N V F S L P N G V E H IS T P A A H T L M E H IS T G E S A H T L M V Q Q Y P E Q R K Q145 4882-8755-5522.2GVLSATILYEILLGKATLYAVLVSAL VLMAMVKRKDSRG SEQ ID NO: MMKSLRVLLVILWLQLSWVWSQQK SEQ ID NO: ATMSNQVLCCVVLCFLGANTVDG N V Y P E Q R K Q L G S T L E F P F T S V G S T L S F P F T S V G H P Q G S A H T L M G S146 4882-8755-5522.2SQSFFWYRQYSGKSPELIMFIYSNGD LDFQATTMFWYRQFPKQSLMLMAT KEDGRFTAQLNKASQYVSLLIRDSQP SNEGSKATYEQGVEKDKFLINHASL SDSATYLCAVSPGRDTGRRALTFGS TLSTLTVTSAHPEDSSFYICSARDKD F A S S E G L M H Y P E Q R K Q L G H E A P A A H T L M T V V D L Q S V A R N N F147 4882-8755-5522.2DKSVCLFTDFDSQTNVSQSKDSDVYI EPSEAEISHTQKATLVCLATGFFPDH TDKTVLDMRSMDFKSNSAVAWSNK VELSWWVNGKEVHSGVSTDPQPLK SDFACANAFNNSIIPEDTFFPSPESSC EQPALNDSRYCLSSRLRVSATFWQN Y S A D Q T E V D L Q S Va e : xempary αβ e ecepor α an an β an mno c equences Identifier α Chain Sequence Identifier β Chain Sequence SEQ ID NO: 475 CAASETSYDKVIF SEQ ID NO: 584 CASSSAQAGDQPQHF148 4882-8755-5522.2SEQ ID NO: 505 CLVTGPSTGGGNKLTF SEQ ID NO: 614 CASSPGTVITDTQYF SEQ ID NO: 506 CIGASNYQLIW SEQ ID NO: 615 CASSVGGGDGQPQHF SEQ ID NO: 507 CAVNGDRDDKIIF SEQ ID NO: 616 CSVEGPPLDYTDTQYF149 4882-8755-5522.2SEQ ID NO: 558 CAARGHNYGQNFVF SEQ ID NO: 667 CASSVGGNYEQYF SEQ ID NO: 559 CALSGSKAAGNKLTF SEQ ID NO: 668 CASKGVGGRETQYF SEQ ID NO: 560 CAVNTGGFKTIF SEQ ID NO: 669 CASSPKASGGSNQPQHF Table 6: Exemplary Predicted αβ T Cell Receptor CDR3 Amino Acid Sequences Identifier Sequence Identifier Sequence Identifier Sequence SEQ ID NO: 693 APAV SEQ ID NO: 743 SFV%GTDT SEQ ID NO: 793 S%DTSSYNE T E E150 4882-8755-5522.2SEQ ID NO: 716 ERGH SEQ ID NO: 766 %TGDSNQP SEQ ID NO: 816 SY%GNTE SEQ ID NO: 717 STTSGG%TDT SEQ ID NO: 767 S%DRGYG SEQ ID NO: 817 SV%GTDT SEQ ID NO: 718 SPG%AGVYE SEQ ID NO: 768 SLGGN%YE SEQ ID NO: 818 SV%YNEcell. The cell may be a Merkel carcinoma cancer cell. The antigen may be the common T cell marker. The antigen may be amino acids 29-41 of the common T cell marker. The antigen may be the large T antigen of MCPyV. The antigen may be amino acids 189-201 or amino acids 97- 109 of the large T antigen of MCPyV. The antigen may be predicted to be other cancer cell antigens, including, but not limited to the large T antigen of MCPyV or the small T antigen of MCPyV when the cancer is Merkel cell carcinoma using bioinformatics methods, such as TCRmodel2. The antigen may include, but is not limited to, amino acid sequences FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843).

[0068] The TCRs, polypeptides, or proteins disclosed herein can be obtained by methods known in the art, such as, for example, de novo synthesis. Polypeptides and proteins can be recombinantly produced using the nucleic acids described herein using standard recombinant methods. See, for instance, Green and Sambrook, Molecular Cloning: A Laboratory Manual, 4th151 4882-8755-5522.2ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2012). Alternatively, the TCRs, polypeptides, and / or proteins described herein can be commercially synthesized by companies. In this respect, the TCRs, polypeptides, and proteins can be synthetic, recombinant, isolated, and / or purified.

[0069] The TCRs may include conjugates, including bioconjugates. Conjugates, as well as methods of synthesizing conjugates in general, are known in the art. III. Cells for treating Merkel cell carcinoma

[0070] Provided herein are cells that may be used to generate an anti-tumor response in a subject with MCC. More specifically, provided herein are cells that express T cellular receptors that are capable of recognizing and binding to antigens present on the surface of the MCC cancer cells. This binding of the cellular receptor to the antigen present on the surface of the MCC cancer cell may activate the cell expressing the cellular receptor. Activation of the cell expressing the cellular receptor may enhance an immune response that targets the MCC cancer cells for destruction through the production of cytokines or through the targeted destruction of the cancer cells.

[0071] The cell may be a cell that expresses a T cell receptor. The cell may endogenously express the T cell receptor. The cell may be genetically engineered to express the T cell receptor. The cell may be a T cell. The T cell can be any type of T cell and can be of any developmental stage, including, but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating leukocytes (TILs), memory T cells (e.g., central memory T cells, effector memory T cells), naïve T cell, and the like. The cell may be a chimeric antigen receptor (CAR) T cell.

[0072] The T cell receptor (TCR) expressed by the cell may be an αβ TCR. The αβ TCR may be encoded by a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at152 4882-8755-5522.2least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 24-46.

[0073] The αβ TCR may include an α TCR chain and a β TCR chain. The α TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840.

[0074] The αβ TCR may have the specific combination of α TCR chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α153 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an154 4882-8755-5522.2amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of155 4882-8755-5522.2SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α156 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an157 4882-8755-5522.2amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of158 4882-8755-5522.2SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5.

[0075] The αβ TCR may be a TCR that recognizes and binds to an antigen on the surface of a cell. The cell may be a cancer cell. The cell may be a Merkel carcinoma cancer cell. The antigen may be the common T cell marker. The antigen may be amino acids 29-41 of the common T cell marker. The antigen may be the large T antigen of MCPyV. The antigen may be amino acids 189-201 or amino acids 97-109 of the large T antigen of MCPyV. The antigen may be predicted to be other cancer cell antigens, including, but not limited to the large T antigen of MCPyV or the small T antigen of MCPyV when the cancer is Merkel cell carcinoma using bioinformatics methods, such as TCRmodel2. The antigen may include, but is not limited to, amino acid sequences FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843).

[0076] Additionally, provided herein are cells that express molecules that may be used to generate an anti-tumor response in a subject with MCC. More specifically provided herein are cells that express various molecules that are capable of activating or enhancing an immune response in a subject. The expression of the molecules may activate surrounding immune cells to target the cancer cells for destruction.

[0077] The cell may be a T cell. The T cell can be any type of T cell and can be of any developmental stage, including, but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating leukocytes (TILs), memory T cells (e.g., central memory T cells, effector memory T cells), naïve T cell, and the like. The cell may be a chimeric antigen receptor (CAR) T cell.159 4882-8755-5522.2

[0078] The cell may be genetically engineered to express molecules that may be used to generate an anti-tumor response. The cell may be contacted with an expression vector comprising a polynucleotide sequence encoding one or more of the molecules that may be used to reduce resistance and / or increase responsiveness to ICB treatment. Molecules that have been identified as being upregulated in the responders to ICB as opposed to non-responders to ICB may be used to generate an anti-tumor response. Molecules that have been identified as being downregulated in non-responders to ICB as opposed to responders to ICB may be used to generate an anti-tumor response. The molecules may be one or more cytokines, chemokines, or receptors. The one or more cytokines, chemokines, or receptors may include, but are not limited to, interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof.

[0079] The cell may be contacted with an expression vector comprising a polynucleotide sequence encoding one or more molecules that are capable of binding to one or more cytokines, chemokines, or receptors to reduce resistance and / or increase responsiveness to ICB treatment. Molecules that have been identified as being upregulated in the non-responders to ICB as opposed to the responders to ICB may be targeted to reduce resistance and modulate the anti- tumor response. Molecules that have been identified as being downregulated in the responders to ICB as opposed to the non-responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. The one or more molecules may bind to one or more cytokines, chemokines, or receptors selected from ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8,160 4882-8755-5522.2IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The molecules may be antibodies, antibody fragments, antigen-binding proteins, or binding agents that specifically recognize any one of the one or more cytokines, chemokines, or receptors. IV. Compositions for treating Merkel cell carcinoma

[0080] Provided herein are compositions that may be used to reduce MCC resistance to ICB treatment.

[0081] First, provided herein are compositions comprising one or more cytokines, chemokines, or receptors or one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance and / or increase responsiveness to ICB treatment.

[0082] Molecules that have been identified as being upregulated in the responders to ICB as opposed to non-responders to ICB may be used to generate an anti-tumor response. Molecules that have been identified as being downregulated in non-responders to ICB as opposed to responders to ICB may be used to generate an anti-tumor response. The composition may include one or more cytokines, chemokines, or receptors selected from interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof.

[0083] The composition may include one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors. Molecules that have been identified as being upregulated in161 4882-8755-5522.2the non-responders to ICB as opposed to the responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. Molecules that have been identified as being downregulated in the responders to ICB as opposed to the non-responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. The one or more molecules may bind to one or more cytokines, chemokines, or receptors selected from ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The molecules may be antibodies, antibody fragments, antigen-binding proteins, or binding agents that specifically recognize any one of the one or more cytokines, chemokines, or receptors.

[0084] The composition may include a combination of the molecules described above, including one or more of the cytokines, chemokines, or receptors that may be used to generate an anti- tumor response and one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance to ICB.

[0085] The compositions may include a pharmaceutically acceptable carrier. The composition may include additional pharmaceutically active agents or therapeutics. The additional pharmaceutically active agent or therapeutic agent may include immune checkpoint blockade treatments.

[0086] The compositions may be formulated for various administrations. Such formulations include any of those suitable for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, intratumoral, or interperitoneal administration. More than one route can be used to administer the compositions, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0087] The polypeptides or proteins disclosed herein can be obtained by methods known in the art, such as, for example, de novo synthesis. Polypeptides and proteins can be recombinantly produced using the nucleic acids described herein using standard recombinant methods. See, for instance, Green and Sambrook, Molecular Cloning: A Laboratory Manual, 4thed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2012). Alternatively, the polypeptides, and / or proteins described herein can be commercially synthesized by companies. In this respect, the162 4882-8755-5522.2polypeptides, and proteins can be synthetic, recombinant, isolated, and / or purified. The polypeptides or proteins may include conjugates, including bioconjugates. Conjugates, as well as methods of synthesizing conjugates in general, are known in the art.

[0088] Thus, provided herein is a composition for generating an anti-tumor response in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises interferon-α, interferon- γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations; (2) topical application, for example, as a cream, ointment or a controlled- release patch or spray applied to the skin; (3) intravaginally or intrarectally, for example, as a pessary, cream or foam; (4) sublingually; (5) ocularly; (6) transdermally; or (7) nasally. The composition may be administered in combination with one or more ICB therapies.

[0089] Also provided herein is a composition for reducing anti-tumor response resistance in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The subject may have immune checkpoint163 4882-8755-5522.2blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations; (2) topical application, for example, as a cream, ointment or a controlled-release patch or spray applied to the skin; (3) intravaginally or intrarectally, for example, as a pessary, cream or foam; (4) sublingually; (5) ocularly; (6) transdermally; or (7) nasally. The composition may be administered in combination with one or more ICB therapies.

[0090] The composition may include a combination of the molecules described above, including one or more of the cytokines, chemokines, or receptors that may be used to generate an anti- tumor response and one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance to ICB. The composition may be administered in combination with one or more ICB therapies.

[0091] Second, provided herein are cellular compositions including cells that express molecules that may be used to generate an anti-tumor response in a subject with MCC. More specifically provided herein are cells that express various molecules that are capable of activating or enhancing an immune response in a subject. The expression of the molecules may activate surrounding immune cells to target the cancer cells for destruction.

[0092] The cell may be a T cell. The T cell can be any type of T cell and can be of any developmental stage, including, but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating leukocytes (TILs), memory T cells (e.g., central memory T cells, effector memory T cells), naïve T cell, and the like. The cell may be a chimeric antigen receptor (CAR) T cell.

[0093] The cell may be genetically engineered to express molecules that may be used to generate an anti-tumor response. The cell may be contacted with one or more expression vectors comprising a polynucleotide sequence encoding one or more of the molecules that may be used to reduce resistance and / or increase responsiveness to ICB treatment. The molecules may be one or more cytokines, chemokines, or receptors. Molecules that have been identified as being164 4882-8755-5522.2upregulated in the responders to ICB as opposed to non-responders to ICB may be used to generate an anti-tumor response. Molecules that have been identified as being downregulated in non-responders to ICB as opposed to responders to ICB may be used to generate an anti-tumor response. The one or more cytokines, chemokines, or receptors may include, but are not limited to, interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof.

[0094] The cell may be contacted with one or more expression vectors comprising a polynucleotide sequence encoding one or more molecules that are capable of binding to one or more cytokines, chemokines, or receptors to reduce resistance and / or increase responsiveness to ICB treatment. Molecules that have been identified as being upregulated in the non-responders to ICB as opposed to the responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. Molecules that have been identified as being downregulated in the responders to ICB as opposed to the non-responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. The one or more molecules may bind to one or more cytokines, chemokines, or receptors selected from ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The molecules may be antibodies, antibody fragments, antigen-binding proteins, or binding agents that specifically recognize any one of the one or more cytokines, chemokines, or receptors.165 4882-8755-5522.2

[0095] The cells may be contacted with one or more expression vectors comprising a polynucleotide sequence encoding a combination of the molecules described above, including one or more of the cytokines, chemokines, or receptors that may be used to generate an anti- tumor response and one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance to ICB.

[0096] The compositions may include a pharmaceutically acceptable carrier. The composition may include additional pharmaceutically active agents or therapeutics. The additional pharmaceutically active agent or therapeutic agent may include immune checkpoint blockade treatments.

[0097] The compositions may be formulated for various administrations. Such formulations include any of those suitable for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, intratumoral, or interperitoneal administration. More than one route can be used to administer the compositions, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0098] Thus, provided herein is a cellular composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising one or more populations of cells genetically modified to express interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition166 4882-8755-5522.2may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more populations of cells may be one or more populations of T cells.

[0099] Also provided herein is a cellular composition for reducing anti-tumor immune response resistance in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising one or more populations of cells genetically modified to express one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more populations of cells may be one or more populations of T cells.

[0100] Third, provided herein are compositions including cells that express T cellular receptors that are capable of recognizing and binding to antigens present on the surface of the MCC cancer cells.

[0101] The cell may be a cell that expresses a T cell receptor. The cell may endogenously express the T cell receptor. The cell may be genetically engineered to express the T cell receptor. The cell may be a T cell. The T cell can be any type of T cell and can be of any developmental stage, including, but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating leukocytes (TILs), memory T cells (e.g., central memory T cells, effector memory T cells), naïve T cell, and the like. The cell may be a chimeric antigen receptor (CAR) T cell.167 4882-8755-5522.2

[0102] The T cell receptor (TCR) expressed by the cell may be an αβ TCR. The αβ TCR may be encoded by a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%,least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 24-46.

[0103] The αβ TCR may include an α TCR chain and a β TCR chain. The α TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least168 4882-8755-5522.294%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840.

[0104] The αβ TCR may have the specific combination of α TCR chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of169 4882-8755-5522.2SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α170 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an171 4882-8755-5522.2amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of172 4882-8755-5522.2SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α173 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5.

[0105] The αβ TCR may be a TCR that recognizes and binds to an antigen on the surface of a cell. The cell may be a cancer cell. The cell may be a Merkel carcinoma cancer cell. The antigen may be the common T cell marker. The antigen may be amino acids 29-41 of the common T cell marker. The antigen may be the large T antigen of MCPyV. The antigen may be amino acids 189-201 or amino acids 97-109 of the large T antigen of MCPyV. The antigen may be predicted to be other cancer cell antigens, including, but not limited to the large T antigen of MCPyV or the small T antigen of MCPyV when the cancer is Merkel cell carcinoma using bioinformatics methods, such as TCRmodel2. The antigen may include, but is not limited to, amino acid sequences FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843).

[0106] The compositions may include a pharmaceutically acceptable carrier. The composition may include additional pharmaceutically active agents or therapeutics. The additional pharmaceutically active agent or therapeutic agent may include immune checkpoint blockade treatments.

[0107] The compositions may be formulated for various administrations. Such formulations include any of those suitable for parenteral, subcutaneous, intravenous, intramuscular,174 4882-8755-5522.2intraarterial, intrathecal, intratumoral, or interperitoneal administration. More than one route can be used to administer the compositions, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0108] Thus, provided herein is a composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma, the composition comprising one or more cell genetically modified to express an αβ T cell receptor (TCR). The αβ TCR may be encoded by a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 24-46. The αβ TCR may include an α TCR chain and a β TCR chain. The α TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%,175 4882-8755-5522.2at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840. The αβ TCR may have the specific combination of α TCR chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino176 4882-8755-5522.2acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID177 4882-8755-5522.2NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR178 4882-8755-5522.2chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino179 4882-8755-5522.2acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID180 4882-8755-5522.2NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5. The αβ TCR may be a TCR that recognizes and binds to an antigen having the amino acid sequence FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843). The subject may have an immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more cells may be one or more T cells. V. Methods for treating Merkel cell carcinoma

[0109] Provided herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating cancer in a subject.181 4882-8755-5522.2

[0110] First, provided herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating cancer and overcoming immune checkpoint blockade (ICB) therapy resistance in a subject having MCC comprising administering to a subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier.

[0111] The one or more cells may be a cell that expresses a T cell receptor. The one or more cells may endogenously express the T cell receptor. The one or more cells may be genetically engineered to express the T cell receptor. The one or more cells may be a T cell. The one or more cells can be any type of T cell and can be of any developmental stage, including, but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating leukocytes (TILs), memory T cells (e.g., central memory T cells, effector memory T cells), naïve T cell, and the like. The one or more cells may be a chimeric antigen receptor (CAR) T cell.

[0112] The T cell receptor (TCR) expressed by the cell may be an αβ TCR. The αβ TCR may be encoded by a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 24-46.

[0113] The αβ TCR may include an α TCR chain and a β TCR chain. The α TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3182 4882-8755-5522.2region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840.

[0114] The αβ TCR may have the specific combination of α TCR chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of183 4882-8755-5522.2SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α184 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an185 4882-8755-5522.2amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of186 4882-8755-5522.2SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α187 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5.

[0115] The αβ TCR may be a TCR that recognizes and binds to an antigen on the surface of a cell. The cell may be a cancer cell. The cell may be a Merkel carcinoma cancer cell. The antigen may be the common T cell marker. The antigen may be amino acids 29-41 of the common T cell188 4882-8755-5522.2marker. The antigen may be the large T antigen of MCPyV. The antigen may be amino acids 189-201 or amino acids 97-109 of the large T antigen of MCPyV. The antigen may be predicted to be other cancer cell antigens, including, but not limited to the large T antigen of MCPyV or the small T antigen of MCPyV when the cancer is Merkel cell carcinoma using bioinformatics methods, such as TCRmodel2. The antigen may include, but is not limited to, amino acid sequences FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843). The composition may include a pharmaceutically acceptable carrier. The composition may include additional pharmaceutically active agents or therapeutics. The additional pharmaceutically active agent or therapeutic agent may include immune checkpoint blockade treatments.

[0116] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0117] Actual dosage levels of the active ingredients (e.g., the one or more cells) in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic or harmful to the patient.

[0118] The selected dosage level will depend upon a variety of factors including the activity of the particular compound (e.g., the one or more cells) of the present disclosure employed, the route of administration, the time of administration, the duration of the treatment, the survival of the one or more cells, other drugs, compounds and / or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health, and prior medical history of the patient being treated, and like factors well known in the medical arts. A189 4882-8755-5522.2physician having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required. For example, the physician could start doses of the composition of the disclosure at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0119] In general, a suitable daily dose of a composition of the disclosure is the amount of the composition that is the lowest dose effective to produce a therapeutic effect. Such an effective dose generally depends on the factors described above.

[0120] If desired, the effective daily dose of the composition may be administered as two, three, four, five, six, seven, eight, nine, ten, or more doses or sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times. Preferred dosing is one administration per day. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, or 21 times a week. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times a month. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days. In some embodiments, the composition is administered every 3 days. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks. In some embodiments, the composition is administered every month. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 months. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 days. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,190 4882-8755-5522.233, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 weeks. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 months. In some embodiments, the composition is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least twice a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least twice a week for a period of at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,191 4882-8755-5522.236, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months.

[0121] The composition may be formulated for various administrations. Such formulations include any of those suitable for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, intratumoral, or interperitoneal administration. More than one route can be used to administer the composition, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0122] The disclosed composition may be administered alone or in combination with one or more additional agents or therapeutics. The one or more additional agents or therapeutics may be immune checkpoint blockade (ICB) treatments. Examples of suitable ICB treatments include, but are not limited to PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG-3 inhibitors, TIM- 3 inhibitors, TIGIT inhibitors, and VISTA inhibitors. The disclosed composition and the one or more additional agent or therapeutic may be administered simultaneously. The disclosed composition and the one or more additional agent or therapeutic may be administered concurrently. The disclosed composition and the one or more additional agent or therapeutic may be administered sequentially. The disclosed composition may be administered prior to administering the one or more additional agent or therapeutic. The disclosed composition may be administered after administering the one or more additional agent or therapeutic. When the composition described herein is co-administered with another, the effective amount may be less than when the composition is used alone.

[0123] Thus, provided herein is a method of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating MCC in a subject, the method comprising administering to the subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier The αβ TCR may be encoded by a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least192 4882-8755-5522.280%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 24-46. The αβ TCR may include an α TCR chain and a β TCR chain. The α TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840. The αβ TCR may have the specific combination of α TCR193 4882-8755-5522.2chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an194 4882-8755-5522.2amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of195 4882-8755-5522.2SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β196 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an197 4882-8755-5522.2amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of198 4882-8755-5522.2SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5. The αβ TCR may be a TCR that recognizes and binds to any one of the amino acid sequences FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843). The subject may have an immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more cells may be one or more T cells. The one or more cells may be genetically modified to express the αβ TCR.

[0124] Provided herein is also a method of overcoming immune checkpoint blockade (ICB) therapy resistance in a subject, the method comprising administering to the subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier. The αβ TCR may be encoded by a nucleotide sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleotide sequences of SEQ ID NOs: 1-23. The αβ TCR may have an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 24-46.The αβ TCR may include an α TCR chain and a β TCR chain. The α TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least199 4882-8755-5522.270%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 47-153. The α TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 261-367. The α TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 475-583. The β TCR chain may be encoded by a nucleotide sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 154-260. The β TCR chain may have an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 368-474. The β TCR chain may include a CDR3 region at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 584-692. The CDR3 of either the α TCR chain or the β TCR chain may be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 693-840. The αβ TCR may have the specific combination of α TCR chain and β TCR chain set forth in Table 3 or Table 4. The αβ TCR may be any combination of the individual α TCR chains and β TCR chains set forth in Table 3 or Table 4. Thus, the αβ TCR may be any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID200 4882-8755-5522.2NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR201 4882-8755-5522.2chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino202 4882-8755-5522.2acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID203 4882-8755-5522.2NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR204 4882-8755-5522.2chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino205 4882-8755-5522.2acid sequence of SEQ ID NO: 474. The αβ TCR may have the specific combination of α TCR chain CDR3 and β TCR chain CDR3 set forth in Table 5. The αβ TCR may be any combination of the individual α TCR chain CDR3s and β TCR chain CDR3s set forth in Table 5. The αβ TCR may be a TCR that recognizes and binds to any one of the amino acid sequences FSFGKAYEY (SEQ ID NO: 841), STPNGTSVPR (SEQ ID NO: 842), or KAAFKRSCL (SEQ ID NO: 843). The subject may have an immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more cells may be one or more T cells. The one or more cells may be genetically modified to express the αβ TCR.

[0125] Additionally provided herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating cancer in a subject comprising administering to a subject an effective amount of a composition comprising one or more cytokines, chemokines, or receptors or one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance and / or increase responsiveness to ICB treatment.

[0126] Molecules that have been identified as being upregulated in the responders to ICB as opposed to non-responders to ICB may be used to generate an anti-tumor response. Molecules that have been identified as being downregulated in non-responders to ICB as opposed to responders to ICB may be used to generate an anti-tumor response. The composition may include one or more cytokines, chemokines, or receptors selected from interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A,206 4882-8755-5522.2TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof.

[0127] The composition may include one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors. Molecules that have been identified as being upregulated in the non-responders to ICB as opposed to the responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. Molecules that have been identified as being downregulated in the responders to ICB as opposed to the non-responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. The one or more molecules may bind to one or more cytokines, chemokines, or receptors selected from ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The molecules may be antibodies, antibody fragments, antigen-binding proteins, or binding agents that specifically recognize any one of the one or more cytokines, chemokines, or receptors.

[0128] The composition may include a combination of the molecules described above, including one or more of the cytokines, chemokines, or receptors that may be used to generate an anti- tumor response and one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance to ICB.

[0129] The composition may include a pharmaceutically acceptable carrier. The composition may include additional pharmaceutically active agents or therapeutics. The additional pharmaceutically active agent or therapeutic agent may include immune checkpoint blockade treatments.

[0130] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated207 4882-8755-5522.2hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0131] Actual dosage levels of the active ingredients (e.g., the one or more cells) in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic or harmful to the patient.

[0132] The selected dosage level will depend upon a variety of factors including the activity of the particular compound (e.g., the one or more cells) of the present disclosure employed, the route of administration, the time of administration, the duration of the treatment, the survival of the one or more cells, other drugs, compounds and / or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health, and prior medical history of the patient being treated, and like factors well known in the medical arts. A physician having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required. For example, the physician could start doses of the composition of the disclosure at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0133] In general, a suitable daily dose of a composition of the disclosure is the amount of the composition that is the lowest dose effective to produce a therapeutic effect. Such an effective dose generally depends on the factors described above.

[0134] If desired, the effective daily dose of the composition may be administered as two, three, four, five, six, seven, eight, nine, ten, or more doses or sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times. Preferred dosing is one administration per day. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, or 21 times a week. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times a month. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,208 4882-8755-5522.219, 20, or 21 days. In some embodiments, the composition is administered every 3 days. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks. In some embodiments, the composition is administered every month. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 months. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 days. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 weeks. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 months. In some embodiments, the composition is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least twice a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,209 4882-8755-5522.266, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least twice a week for a period of at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months.

[0135] The composition may be formulated for various administrations. Such formulations include any of those suitable for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, intratumoral, or interperitoneal administration. More than one route can be used to administer the composition, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0136] The disclosed composition may be administered alone or in combination with one or more additional agents or therapeutics. The one or more additional agents or therapeutics may be immune checkpoint blockade (ICB) treatments. Examples of suitable ICB treatments include, but are not limited to PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG-3 inhibitors, TIM- 3 inhibitors, TIGIT inhibitors, and VISTA inhibitors. The disclosed composition and the one or210 4882-8755-5522.2more additional agent or therapeutic may be administered simultaneously. The disclosed composition and the one or more additional agent or therapeutic may be administered concurrently. The disclosed composition and the one or more additional agent or therapeutic may be administered sequentially. The disclosed composition may be administered prior to administering the one or more additional agent or therapeutic. The disclosed composition may be administered after administering the one or more additional agent or therapeutic. When the composition described herein is co-administered with another, the effective amount may be less than when the composition is used alone.

[0137] Additionally provided herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating cancer in a subject comprising administering to a subject an effective amount of a composition comprising one or more cells comprising various molecules that are capable of activating or enhancing an immune response in a subject.

[0138] The cell may be a T cell. The T cell can be any type of T cell and can be of any developmental stage, including, but not limited to, CD4+ / CD8+ double positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating leukocytes (TILs), memory T cells (e.g., central memory T cells, effector memory T cells), naïve T cell, and the like. The cell may be a chimeric antigen receptor (CAR) T cell.

[0139] The cell may be genetically engineered to express molecules that may be used to generate an anti-tumor response. The cell may be contacted with one or more expression vectors comprising a polynucleotide sequence encoding one or more of the molecules that may be used to reduce resistance and / or increase responsiveness to ICB treatment. The molecules may be one or more cytokines, chemokines, or receptors. Molecules that have been identified as being upregulated in the responders to ICB as opposed to non-responders to ICB may be used to generate an anti-tumor response. Molecules that have been identified as being downregulated in non-responders to ICB as opposed to responders to ICB may be used to generate an anti-tumor response. The one or more cytokines, chemokines, or receptors may include, but are not limited to, interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40,211 4882-8755-5522.2CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof, or a functional fragment thereof. The cell may be contacted with one or more expression vectors comprising a polynucleotide sequence encoding one or more molecules that are capable of binding to one or more cytokines, chemokines, or receptors to reduce resistance and / or increase responsiveness to ICB treatment. Molecules that have been identified as being upregulated in the non-responders to ICB as opposed to the responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. Molecules that have been identified as being downregulated in the responders to ICB as opposed to the non- responders to ICB may be targeted to reduce resistance and modulate the anti-tumor response. The one or more molecules may bind to one or more cytokines, chemokines, or receptors selected from ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The molecules may be antibodies, antibody fragments, antigen-binding proteins, or binding agents that specifically recognize any one of the one or more cytokines, chemokines, or receptors.

[0140] The cell may be contacted with one or more expression vectors comprising a polynucleotide sequence encoding a combination of the molecules described above, including one or more of the cytokines, chemokines, or receptors that may be used to generate an anti- tumor response and one or more molecules that inhibit binding of one or more cytokines, chemokines, or receptors that may be used to reduce resistance to ICB.

[0141] The composition may include a pharmaceutically acceptable carrier. The composition may include additional pharmaceutically active agents or therapeutics. The additional212 4882-8755-5522.2pharmaceutically active agent or therapeutic agent may include immune checkpoint blockade treatments.

[0142] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0143] Actual dosage levels of the active ingredients (e.g., the one or more cells) in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic or harmful to the patient.

[0144] The selected dosage level will depend upon a variety of factors including the activity of the particular compound (e.g., the one or more cells) of the present disclosure employed, the route of administration, the time of administration, the duration of the treatment, the survival of the one or more cells, other drugs, compounds and / or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health, and prior medical history of the patient being treated, and like factors well known in the medical arts. A physician having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required. For example, the physician could start doses of the composition of the disclosure at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0145] In general, a suitable daily dose of a composition of the disclosure is the amount of the composition that is the lowest dose effective to produce a therapeutic effect. Such an effective dose generally depends on the factors described above.213 4882-8755-5522.2

[0146] If desired, the effective daily dose of the composition may be administered as two, three, four, five, six, seven, eight, nine, ten, or more doses or sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times. Preferred dosing is one administration per day. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, or 21 times a week. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times a month. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days. In some embodiments, the composition is administered every 3 days. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks. In some embodiments, the composition is administered every month. In some embodiments, the composition is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 months. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 days. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 weeks. In some embodiments, the composition is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 times over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 months. In some embodiments, the composition is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,214 4882-8755-5522.232, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least twice a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least twice a week for a period of at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the composition is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the composition is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months.

[0147] The composition may be formulated for various administrations. Such formulations include any of those suitable for parenteral, subcutaneous, intravenous, intramuscular,215 4882-8755-5522.2intraarterial, intrathecal, intratumoral, or interperitoneal administration. More than one route can be used to administer the composition, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0148] The disclosed composition may be administered alone or in combination with one or more additional agents or therapeutics. The one or more additional agents or therapeutics may be immune checkpoint blockade (ICB) treatments. Examples of suitable ICB treatments include, but are not limited to PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG-3 inhibitors, TIM- 3 inhibitors, TIGIT inhibitors, and VISTA inhibitors. The disclosed composition and the one or more additional agent or therapeutic may be administered simultaneously. The disclosed composition and the one or more additional agent or therapeutic may be administered concurrently. The disclosed composition and the one or more additional agent or therapeutic may be administered sequentially. The disclosed composition may be administered prior to administering the one or more additional agent or therapeutic. The disclosed composition may be administered after administering the one or more additional agent or therapeutic. When the composition described herein is co-administered with another, the effective amount may be less than when the composition is used alone.

[0149] Thus, provided herein is a method for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating MCC in a subject comprising administering to the subject an effective amount of a composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10,216 4882-8755-5522.2TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies.

[0150] Provided herein is a method for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating MCC in a subject comprising administering to the subject an effective amount of a composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies.

[0151] Provided herein is a method for treating, prevent, inhibiting, reducing the incidence of, ameliorating or alleviating MCC in a subject comprising administering to the subject an effective amount of a cellular composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising one or more populations of cells genetically modified to express interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18,217 4882-8755-5522.2IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more populations of cells is one or more populations of T cells.

[0152] Provided herein is a method for treating, prevent, inhibiting, reducing the incidence of, ameliorating or alleviating MCC in a subject comprising administering to the subject an effective amount of a cellular composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising one or more populations of cells genetically modified to express one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more populations of cells is one or more populations of T cells.

[0153] Provided herein is a method for overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with Merkel cell carcinoma (MCC) in a subject comprising administering to the subject an effective amount of a composition for generating an anti-tumor immune218 4882-8755-5522.2response in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies.

[0154] Provided herein is a method for overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with MCC in a subject comprising administering to the subject an effective amount of a composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies.219 4882-8755-5522.2

[0155] Provided herein is a method for overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with MCC in a subject comprising administering to the subject an effective amount of a cellular composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising one or more populations of cells genetically modified to express interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof. The subject may have immune checkpoint blockade (ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more populations of cells is one or more populations of T cells.

[0156] Provided herein is a method for overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with MCC in a subject comprising administering to the subject an effective amount of a cellular composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising one or more populations of cells genetically modified to express one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof. The subject may have immune checkpoint blockade220 4882-8755-5522.2(ICB) therapy resistant MCC. The composition may be specially formulated for administration in solid or liquid form, including, but not limited to, parenteral administration, for example, by subcutaneous, intramuscular, intravenous, or epidural injection as, for example, a sterile solution or suspension, or sustained release formulations. The composition may be administered in combination with one or more ICB therapies. The one or more populations of cells is one or more populations of T cells.

[0157] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates that may need to be independently confirmed. EXAMPLES

[0158] The present technology is further illustrated by the following Examples, which should not be construed as limiting in any way. Example 1: Pre-existing skin-resident CD8 cell circuits mediate immune response in Merkel cell carcinoma and predict immunotherapy efficacy

[0159] Compilation of a clinically and molecularly annotated MCC cohort

[0160] The largest multi-institutional MCC dataset was collected with multi-modal molecular characterization of 186 samples across 116 patients including 92 patients with evaluable ICB responses (Table 7, FIGS.1A and 2-3). These include bulk RNA-Seq (n = 85 samples from 71 patients) (FIG.2A) and a modified form of ECCITE-Seq (n = 54 tumor samples from 48 patients; n = 55 blood samples from 32 patients) (FIG.2B), including three samples previously reported. Moreover, 44 distinct samples were spatially profiled using multiplex immunofluorescence (mIF) imaging (Akoya Phenoimager), spatial cancer gene or whole transcriptome profiling (Nanostring GeoMx), and single-cell resolution spatial transcriptomics221 4882-8755-5522.2(Nanostring CosMx) (FIGS.1B and 2C). Overall, 63 patients in this dataset were profiled using two or more modalities (FIG.3). Table 7: Clinical characteristics of patients included in the study with odds ratio of how characteristics affect immunotherapy response Characteristics CR PR Total SD PD Total Non- NA No P OR 95% Responders Responders ICB value CI 9- 2 8- 8 0- 4 1- 0 2- 2 8- 2 1- 52 0- 7222 4882-8755-5522.2Radiation Naïve Yes 7 13 20 2 20 22 6 0 0.55 0.77 0.34- 6 1- 9 5- 18 6- 2 5- 8 6- 8 2- 2 2- 3

[0161] Bulk RNA-Seq reveals predictive biomarkers of response to ICB

[0162] First, the bulk RNA-seq of tumors, pre-ICB, was analyzed from a cohort of 63 patients with 62 patients that were systemic treatment naive to minimize confounding variables related to prior therapy. Within this dataset, there were 31 responders (partial or complete response) and 32 non-responders (stable and / or progressive disease) (FIG.2A).223 4882-8755-5522.2

[0163] Differential gene expression analysis revealed 800 upregulated genes in responders and 436 in non-responders (padj < 0.1, DESeq2.0) (FIG.1C). Many of the genes are characteristic of CD8 T cells (αβ TCR, GZMA, CD8A, CD8B), γδ T cells (γδ TCRs), B cells (IG genes, CD79A), and plasmacytoid dendritic cells (TLR7, LILRB4). Several molecules were associated with tumor-specific cytotoxic T cells, including markers of T cell exhaustion (HAVCR2, LAG3, and TIGIT) and cytotoxic activity (GZMB and PRF1). Collectively, these data suggest an enrichment of pre-existing CD8 T cells, B cells, and specific myeloid subtypes in responders.

[0164] Pathway analysis with Enrichr(9) showed upregulation of IFN-γ signaling (Padj. = 2.22e- 63), IFN-α signaling (Padj= 8.53e-52), and antigen presentation machinery (Padj.= 2.36e-17), associated with IFN-γ signaling in other cancers including melanoma (FIGS.1D-1E).

[0165] Non-responders had upregulated MCC-specific genes, like PAX6 and FOXA1. Pathway analysis revealed additional enrichment of genes associated: 1) IL-1 processing, including IL1A and IL1B, and 2) E2F targets, which are normally expressed during cell division (FIGS.1F-1G).

[0166] Single cell RNA-Seq reveals cellular composition of the tumor microenvironment and blood

[0167] Next, single-cell RNA sequencing (scRNA-Seq) was conducted initially on 49 tumor samples derived from 43 patients (FIG.2B). This included 8 samples from 4 patients across two timepoints (including 2 pairs of samples collected before and after ICB), 4 samples from 2 patients spanning different tissues (skin / lymph node pairs), and 37 single samples. Additionally, 55 peripheral blood mononuclear cell (PBMC) samples from 32 patients were analyzed. This included 21 pre / post-ICB pairs (42 samples), 2 samples from a third timepoint, and 11 samples that were unmatched. 26 of these samples were matched to patients that also had scRNA-Seq on tumor tissue. (FIGS.1A-1B and 4-6).313,757 cells were recovered from these samples using scRNA-Seq. An additional cohort of 5 post treatment tumor samples with 46,312 cells were integrated and analyzed separately to investigate the cellular landscape after ICB for a total of 360,069 cells. Following quality control, 27 distinct cell types were identified in the tumor immune microenvironment, including CD8 T cells, CD4 T cells, natural killer (NK) cells, γδ T cells, macrophages, dendritic cells, plasma cells, B cells, and plasmacytoid dendritic cell (pDC) clusters (FIGS.7A-7B, 4, and 5A).224 4882-8755-5522.2

[0168] Type I and II Interferon signatures in tumor cells predict response

[0169] First, the 60,902 tumor cells were analyzed; these cells were marked by the expression of neuroendocrine transcription factor ATOH1 and chromogranin. Expression of the viral oncogenes smal...

Claims

CLAIMS What is claimed is:

1. A composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), wherein the composition comprises: (i) at least one of interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R, CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof; (ii) one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to at least one of ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof; or (iii) a combination of (i) and (ii).

2. The composition of claim 1, wherein the subject has immune checkpoint blockade (ICB) therapy resistant MCC.

3. The composition of claim 1, wherein the composition is administered in combination with one or more ICB therapies.

4. A cellular composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the cellular composition comprising (i) one or more populations of cells genetically modified to express at least one of interferon-α, interferon-γ, ACVR1, BTLA, CCL13, CCL18, CCL2, CCL22, CCL4, CCL4L2, CCL5, CCL8, CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CD27, CD4, CD40, CD40LG, CD70, CD80, CD86, CSF1, CSF1R,251 4882-8755-5522.2CSF2RB, CSF3, CSF3R, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL9, CXCR2, CXCR4, CXCR6, FAS, FASLG, GDF10, GHR, ICOSL, IFI16, IFI27, IFNG, IFNGR1, IFNW1, IL10RA, IL10RB, IL12RB1, IL13RA1, IL15, IL15RA, IL16, IL17RC, IL-18, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RN, IL27RA, IL2RA, IL2RB, IL2RG, IL32, IL33, IL34, IL4R, IL6, IL6R, IL6ST, IL7R, INFA2, INHBA, IRF1, IRF9, ITBG2, LIF, LIFR, LTB, MX1, OAS1, OSM, STAT1, TGFB1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF12A, TNFRSF13B, TNFRSF14, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF8, TNFSF9, VCAM1, or a functional fragment thereof; (ii) one or more populations of cells genetically modified to express one or more antibodies or antibody fragments, wherein the one or more antibodies or antibody fragments bind to at least one of ACVR2B, AMH, CSF3, GDF11, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNK, IFNW1, IL-1, IL1A, IL1B, OTX2, or a functional fragment thereof; or (iii) a combination of (i) and (ii).

5. The cellular composition of claim 4, wherein the subject has immune checkpoint blockade (ICB) therapy resistant MCC.

6. The composition of claim 4, wherein the composition is administered in combination with one or more ICB therapies.

7. The cellular composition of claim 4, wherein the one or more populations of cells is one or more populations of T cells.

8. A method for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating Merkel cell carcinoma (MCC) in a subject comprising administering to the subject an effective amount of the composition of any one of claims 1-7.

9. A method for overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with Merkel cell carcinoma (MCC) comprising administering to the subject an effective amount of the composition of any one of claims 1-7.252 4882-8755-5522.

210. A composition for generating an anti-tumor immune response in a subject with Merkel cell carcinoma (MCC), the composition comprising one or more cells genetically modified to express an αβ T cell receptor (TCR).

11. The composition of claim 10, wherein the αβ TCR comprises an amino acid sequence at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NOs: 24-46.

12. The composition of claim 10, wherein the TCR comprises an α TCR chain and a β TCR chain.

13. The composition of claim 12, wherein the α TCR chain and a β TCR chain at least 90% identical to any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an253 4882-8755-5522.2amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of254 4882-8755-5522.2SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β255 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an256 4882-8755-5522.2amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of257 4882-8755-5522.2SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO:

474.

14. The composition of claim 10, wherein the subject has immune checkpoint blockade (ICB) therapy resistant MCC.

15. The composition of claim 10, wherein the composition is administered in combination with one or more ICB therapies.

16. The composition of claim 10, wherein the one or more cells are one or more T cells.

17. A method of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating Merkel cell carcinoma (MCC) in a subject, the method comprising administering to the subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier.

18. The method of claim 17, wherein the αβ TCR comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NOs: 24-46.258 4882-8755-5522.

219. The method of claim 17, wherein the αβ TCR comprises a TCR α chain and a TCR β chain.

20. The method of claim 19, wherein the α TCR chain and a β TCR chain at least 90% identical to any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β259 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an260 4882-8755-5522.2amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of261 4882-8755-5522.2SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β262 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an263 4882-8755-5522.2amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO:

474.

21. The method of claim 17, wherein the subject has immune checkpoint blockade (ICB) therapy resistant MCC.

22. The method of claim 17, wherein the composition is administered in combination with one or more ICB therapies.

23. The method of claim 17, wherein the one or more cells are one or more T cells.

24. The method of claim 17, wherein the one or more cells are genetically modified to express the αβ TCR.

25. A method of overcoming immune checkpoint blockade (ICB) therapy resistance in a subject with ICB therapy resistant Merkel cell carcinoma (MCC), the method comprising administering to the subject an effective amount of a composition comprising one or more cells expressing an αβ T cell receptor (TCR) and a pharmaceutically acceptable carrier.

26. The method of claim 25, wherein the αβ TCR comprises an amino acid sequence at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NOs: 24-46.

27. The method of claim 25, wherein the αβ TCR comprises a TCR α chain and a TCR β chain.

28. The method of claim 27, wherein the α TCR chain and a β TCR chain at least 90% identical to any one of: an α TCR chain having an amino acid sequence of SEQ ID NO: 261 and264 4882-8755-5522.2a β TCR chain having an amino acid sequence of SEQ ID NO: 368; an α TCR chain having an amino acid sequence of SEQ ID NO: 262 and a β TCR chain having an amino acid sequence of SEQ ID NO: 369; an α TCR chain having an amino acid sequence of SEQ ID NO: 263 and a β TCR chain having an amino acid sequence of SEQ ID NO: 370; an α TCR chain having an amino acid sequence of SEQ ID NO: 264 and a β TCR chain having an amino acid sequence of SEQ ID NO: 371; an α TCR chain having an amino acid sequence of SEQ ID NO: 265 and a β TCR chain having an amino acid sequence of SEQ ID NO: 372; an α TCR chain having an amino acid sequence of SEQ ID NO: 266 and a β TCR chain having an amino acid sequence of SEQ ID NO: 373; an α TCR chain having an amino acid sequence of SEQ ID NO: 267 and a β TCR chain having an amino acid sequence of SEQ ID NO: 374; an α TCR chain having an amino acid sequence of SEQ ID NO: 268 and a β TCR chain having an amino acid sequence of SEQ ID NO: 375; an α TCR chain having an amino acid sequence of SEQ ID NO: 269 and a β TCR chain having an amino acid sequence of SEQ ID NO: 376; an α TCR chain having an amino acid sequence of SEQ ID NO: 270 and a β TCR chain having an amino acid sequence of SEQ ID NO: 377; an α TCR chain having an amino acid sequence of SEQ ID NO: 271 and a β TCR chain having an amino acid sequence of SEQ ID NO: 378; an α TCR chain having an amino acid sequence of SEQ ID NO: 272 and a β TCR chain having an amino acid sequence of SEQ ID NO: 379; an α TCR chain having an amino acid sequence of SEQ ID NO: 273 and a β TCR chain having an amino acid sequence of SEQ ID NO: 380; an α TCR chain having an amino acid sequence of SEQ ID NO: 274 and a β TCR chain having an amino acid sequence of SEQ ID NO: 381; an α TCR chain having an amino acid sequence of SEQ ID NO: 275 and a β TCR chain having an amino acid sequence of SEQ ID NO: 382; an α TCR chain having an amino acid sequence of SEQ ID NO: 276 and a β TCR chain having an amino acid sequence of SEQ ID NO: 383; an α TCR chain having an amino acid sequence of SEQ ID NO: 277 and a β TCR chain having an amino acid sequence of SEQ ID NO: 384; an α TCR chain having an amino acid sequence of SEQ ID NO: 278 and a β TCR chain having an amino acid sequence of SEQ ID NO: 385; an α TCR chain having an amino acid sequence of SEQ ID NO: 279 and a β TCR chain having an amino acid sequence of SEQ ID NO: 386; an α TCR chain having an amino acid sequence of SEQ ID NO: 280 and a β TCR chain having an amino acid sequence of SEQ ID NO: 387; an α TCR chain having an amino acid sequence of SEQ ID NO: 281 and a β TCR chain having an amino acid sequence of SEQ ID NO: 388; an α TCR chain having an265 4882-8755-5522.2amino acid sequence of SEQ ID NO: 282 and a β TCR chain having an amino acid sequence of SEQ ID NO: 389; an α TCR chain having an amino acid sequence of SEQ ID NO: 283 and a β TCR chain having an amino acid sequence of SEQ ID NO: 390; an α TCR chain having an amino acid sequence of SEQ ID NO: 284 and a β TCR chain having an amino acid sequence of SEQ ID NO: 391; an α TCR chain having an amino acid sequence of SEQ ID NO: 285 and a β TCR chain having an amino acid sequence of SEQ ID NO: 392; an α TCR chain having an amino acid sequence of SEQ ID NO: 286 and a β TCR chain having an amino acid sequence of SEQ ID NO: 393; an α TCR chain having an amino acid sequence of SEQ ID NO: 287 and a β TCR chain having an amino acid sequence of SEQ ID NO: 394; an α TCR chain having an amino acid sequence of SEQ ID NO: 288 and a β TCR chain having an amino acid sequence of SEQ ID NO: 395; an α TCR chain having an amino acid sequence of SEQ ID NO: 289 and a β TCR chain having an amino acid sequence of SEQ ID NO: 396; an α TCR chain having an amino acid sequence of SEQ ID NO: 290 and a β TCR chain having an amino acid sequence of SEQ ID NO: 397; an α TCR chain having an amino acid sequence of SEQ ID NO: 291 and a β TCR chain having an amino acid sequence of SEQ ID NO: 398; an α TCR chain having an amino acid sequence of SEQ ID NO: 292 and a β TCR chain having an amino acid sequence of SEQ ID NO: 399; an α TCR chain having an amino acid sequence of SEQ ID NO: 293 and a β TCR chain having an amino acid sequence of SEQ ID NO: 400; an α TCR chain having an amino acid sequence of SEQ ID NO: 294 and a β TCR chain having an amino acid sequence of SEQ ID NO: 401; an α TCR chain having an amino acid sequence of SEQ ID NO: 295 and a β TCR chain having an amino acid sequence of SEQ ID NO: 402; an α TCR chain having an amino acid sequence of SEQ ID NO: 296 and a β TCR chain having an amino acid sequence of SEQ ID NO: 403; an α TCR chain having an amino acid sequence of SEQ ID NO: 297 and a β TCR chain having an amino acid sequence of SEQ ID NO: 404; an α TCR chain having an amino acid sequence of SEQ ID NO: 298 and a β TCR chain having an amino acid sequence of SEQ ID NO: 405; an α TCR chain having an amino acid sequence of SEQ ID NO: 299 and a β TCR chain having an amino acid sequence of SEQ ID NO: 406; an α TCR chain having an amino acid sequence of SEQ ID NO: 300 and a β TCR chain having an amino acid sequence of SEQ ID NO: 407; an α TCR chain having an amino acid sequence of SEQ ID NO: 301 and a β TCR chain having an amino acid sequence of SEQ ID NO: 408; an α TCR chain having an amino acid sequence of SEQ ID NO: 302 and a β TCR chain having an amino acid sequence of266 4882-8755-5522.2SEQ ID NO: 409; an α TCR chain having an amino acid sequence of SEQ ID NO: 303 and a β TCR chain having an amino acid sequence of SEQ ID NO: 410; an α TCR chain having an amino acid sequence of SEQ ID NO: 304 and a β TCR chain having an amino acid sequence of SEQ ID NO: 411; an α TCR chain having an amino acid sequence of SEQ ID NO: 305 and a β TCR chain having an amino acid sequence of SEQ ID NO: 412; an α TCR chain having an amino acid sequence of SEQ ID NO: 306 and a β TCR chain having an amino acid sequence of SEQ ID NO: 413; an α TCR chain having an amino acid sequence of SEQ ID NO: 307 and a β TCR chain having an amino acid sequence of SEQ ID NO: 414; an α TCR chain having an amino acid sequence of SEQ ID NO: 308 and a β TCR chain having an amino acid sequence of SEQ ID NO: 415; an α TCR chain having an amino acid sequence of SEQ ID NO: 309 and a β TCR chain having an amino acid sequence of SEQ ID NO: 416; an α TCR chain having an amino acid sequence of SEQ ID NO: 310 and a β TCR chain having an amino acid sequence of SEQ ID NO: 417; an α TCR chain having an amino acid sequence of SEQ ID NO: 311 and a β TCR chain having an amino acid sequence of SEQ ID NO: 418; an α TCR chain having an amino acid sequence of SEQ ID NO: 312 and a β TCR chain having an amino acid sequence of SEQ ID NO: 419; an α TCR chain having an amino acid sequence of SEQ ID NO: 313 and a β TCR chain having an amino acid sequence of SEQ ID NO: 420; an α TCR chain having an amino acid sequence of SEQ ID NO: 314 and a β TCR chain having an amino acid sequence of SEQ ID NO: 421; an α TCR chain having an amino acid sequence of SEQ ID NO: 315 and a β TCR chain having an amino acid sequence of SEQ ID NO: 422; an α TCR chain having an amino acid sequence of SEQ ID NO: 316 and a β TCR chain having an amino acid sequence of SEQ ID NO: 423; an α TCR chain having an amino acid sequence of SEQ ID NO: 317 and a β TCR chain having an amino acid sequence of SEQ ID NO: 424; an α TCR chain having an amino acid sequence of SEQ ID NO: 318 and a β TCR chain having an amino acid sequence of SEQ ID NO: 425; an α TCR chain having an amino acid sequence of SEQ ID NO: 319 and a β TCR chain having an amino acid sequence of SEQ ID NO: 426; an α TCR chain having an amino acid sequence of SEQ ID NO: 320 and a β TCR chain having an amino acid sequence of SEQ ID NO: 427; an α TCR chain having an amino acid sequence of SEQ ID NO: 321 and a β TCR chain having an amino acid sequence of SEQ ID NO: 428; an α TCR chain having an amino acid sequence of SEQ ID NO: 322 and a β TCR chain having an amino acid sequence of SEQ ID NO: 429; an α TCR chain having an amino acid sequence of SEQ ID NO: 323 and a β267 4882-8755-5522.2TCR chain having an amino acid sequence of SEQ ID NO: 430; an α TCR chain having an amino acid sequence of SEQ ID NO: 324 and a β TCR chain having an amino acid sequence of SEQ ID NO: 431; an α TCR chain having an amino acid sequence of SEQ ID NO: 325 and a β TCR chain having an amino acid sequence of SEQ ID NO: 432; an α TCR chain having an amino acid sequence of SEQ ID NO: 326 and a β TCR chain having an amino acid sequence of SEQ ID NO: 433; an α TCR chain having an amino acid sequence of SEQ ID NO: 327 and a β TCR chain having an amino acid sequence of SEQ ID NO: 434; an α TCR chain having an amino acid sequence of SEQ ID NO: 328 and a β TCR chain having an amino acid sequence of SEQ ID NO: 435; an α TCR chain having an amino acid sequence of SEQ ID NO: 329 and a β TCR chain having an amino acid sequence of SEQ ID NO: 436; an α TCR chain having an amino acid sequence of SEQ ID NO: 330 and a β TCR chain having an amino acid sequence of SEQ ID NO: 437; an α TCR chain having an amino acid sequence of SEQ ID NO: 331 and a β TCR chain having an amino acid sequence of SEQ ID NO: 438; an α TCR chain having an amino acid sequence of SEQ ID NO: 332 and a β TCR chain having an amino acid sequence of SEQ ID NO: 439; an α TCR chain having an amino acid sequence of SEQ ID NO: 333 and a β TCR chain having an amino acid sequence of SEQ ID NO: 440; an α TCR chain having an amino acid sequence of SEQ ID NO: 334 and a β TCR chain having an amino acid sequence of SEQ ID NO: 441; an α TCR chain having an amino acid sequence of SEQ ID NO: 335 and a β TCR chain having an amino acid sequence of SEQ ID NO: 442; an α TCR chain having an amino acid sequence of SEQ ID NO: 336 and a β TCR chain having an amino acid sequence of SEQ ID NO: 443; an α TCR chain having an amino acid sequence of SEQ ID NO: 337 and a β TCR chain having an amino acid sequence of SEQ ID NO: 444; an α TCR chain having an amino acid sequence of SEQ ID NO: 338 and a β TCR chain having an amino acid sequence of SEQ ID NO: 445; an α TCR chain having an amino acid sequence of SEQ ID NO: 339 and a β TCR chain having an amino acid sequence of SEQ ID NO: 446; an α TCR chain having an amino acid sequence of SEQ ID NO: 340 and a β TCR chain having an amino acid sequence of SEQ ID NO: 447; an α TCR chain having an amino acid sequence of SEQ ID NO: 341 and a β TCR chain having an amino acid sequence of SEQ ID NO: 448; an α TCR chain having an amino acid sequence of SEQ ID NO: 342 and a β TCR chain having an amino acid sequence of SEQ ID NO: 449; an α TCR chain having an amino acid sequence of SEQ ID NO: 343 and a β TCR chain having an amino acid sequence of SEQ ID NO: 450; an α TCR chain having an268 4882-8755-5522.2amino acid sequence of SEQ ID NO: 344 and a β TCR chain having an amino acid sequence of SEQ ID NO: 451; an α TCR chain having an amino acid sequence of SEQ ID NO: 345 and a β TCR chain having an amino acid sequence of SEQ ID NO: 452; an α TCR chain having an amino acid sequence of SEQ ID NO: 346 and a β TCR chain having an amino acid sequence of SEQ ID NO: 453; an α TCR chain having an amino acid sequence of SEQ ID NO: 347 and a β TCR chain having an amino acid sequence of SEQ ID NO: 454; an α TCR chain having an amino acid sequence of SEQ ID NO: 348 and a β TCR chain having an amino acid sequence of SEQ ID NO: 455; an α TCR chain having an amino acid sequence of SEQ ID NO: 349 and a β TCR chain having an amino acid sequence of SEQ ID NO: 456; an α TCR chain having an amino acid sequence of SEQ ID NO: 350 and a β TCR chain having an amino acid sequence of SEQ ID NO: 457; an α TCR chain having an amino acid sequence of SEQ ID NO: 351 and a β TCR chain having an amino acid sequence of SEQ ID NO: 458; an α TCR chain having an amino acid sequence of SEQ ID NO: 352 and a β TCR chain having an amino acid sequence of SEQ ID NO: 459; an α TCR chain having an amino acid sequence of SEQ ID NO: 353 and a β TCR chain having an amino acid sequence of SEQ ID NO: 460; an α TCR chain having an amino acid sequence of SEQ ID NO: 354 and a β TCR chain having an amino acid sequence of SEQ ID NO: 461; an α TCR chain having an amino acid sequence of SEQ ID NO: 355 and a β TCR chain having an amino acid sequence of SEQ ID NO: 462; an α TCR chain having an amino acid sequence of SEQ ID NO: 356 and a β TCR chain having an amino acid sequence of SEQ ID NO: 463; an α TCR chain having an amino acid sequence of SEQ ID NO: 357 and a β TCR chain having an amino acid sequence of SEQ ID NO: 464; an α TCR chain having an amino acid sequence of SEQ ID NO: 358 and a β TCR chain having an amino acid sequence of SEQ ID NO: 465; an α TCR chain having an amino acid sequence of SEQ ID NO: 359 and a β TCR chain having an amino acid sequence of SEQ ID NO: 466; an α TCR chain having an amino acid sequence of SEQ ID NO: 360 and a β TCR chain having an amino acid sequence of SEQ ID NO: 467; an α TCR chain having an amino acid sequence of SEQ ID NO: 361 and a β TCR chain having an amino acid sequence of SEQ ID NO: 468; an α TCR chain having an amino acid sequence of SEQ ID NO: 362 and a β TCR chain having an amino acid sequence of SEQ ID NO: 469; an α TCR chain having an amino acid sequence of SEQ ID NO: 363 and a β TCR chain having an amino acid sequence of SEQ ID NO: 470; an α TCR chain having an amino acid sequence of SEQ ID NO: 364 and a β TCR chain having an amino acid sequence of269 4882-8755-5522.2SEQ ID NO: 471; an α TCR chain having an amino acid sequence of SEQ ID NO: 365 and a β TCR chain having an amino acid sequence of SEQ ID NO: 472; an α TCR chain having an amino acid sequence of SEQ ID NO: 366 and a β TCR chain having an amino acid sequence of SEQ ID NO: 473; or an α TCR chain having an amino acid sequence of SEQ ID NO: 367 and a β TCR chain having an amino acid sequence of SEQ ID NO:

474.

29. The method of claim 25, wherein the composition is administered in combination with one or more ICB therapies.

30. The method of claim 25, wherein the one or more cells are one or more T cells.

31. The method of claim 25, wherein the one or more cells are genetically modified to express the αβ TCR.270 4882-8755-5522.2

Citation Information

Patent Citations

  • Combination therapies of microorganisms and immune modulators for use in treating cancer

    US20220023358A1

  • Desmoglein 2-directed chimeric antigen receptor (CAR) constructs and methods of use

    WO2022120010A1

Cited By

  • Gamma-delta t cell receptors for cancer therapy

    WO2025231488A1